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Abstract
N-linked glycosylation is a ubiquitous form of protein modification whereby a preassembled
oligosaccharide is covalently attached the asparagine side chain of an acceptor protein. This
process involves numerous enzymes, produces a diverse set of oligosaccharide structures, and
results in a variety of structural and functional effects on the glycoprotein. Research discussed in
this dissertation applies synthetic organic chemistry to probe this important biological system.
To study the effects of N-linked glycosylation on protein folding, a semi-synthetic strategy was
developed to access a set of model proteins that were homogeneously glycosylated at several
sites of interest. The folding kinetics of this set of glycoproteins were then characterized using
stopped-flow fluorescence spectroscopy, which revealed that the presence of the glycan show
discrete effects on both the rate of protein folding and unfolding, and that the overall effect is
highly specific to the local primary and secondary structure of the glycosylation site.
The gram-negative bacterium Campylobacterjejuni was recently discovered to contain a general
N-linked glycosylation system with a defined glycan structure and tractable enzymes for
heterologous expression including a single subunit oligosaccharyltransferase. To probe the
bacterial N-linked glycosylation machinery, a chemo-enzymatic synthesis for each of the glycan
intermediates within this pathway was developed, which are impractical to obtain from the host
organism. Importantly, chemo-enzymatic allowed for the incorporation of structural
modifications for binding-specificity assays and radiolabels for accurate quantification. Access
to these substrates allowed us to define the minimum glycosylation consensus sequence for the
oligosaccharyltransferase as well as the polyisoprenol specificity of three representative enzymes
within the pathway.
Thesis Supervisor: Barbara Imperiali
Class of 1922 Professor of Chemistry and Professor of Biology
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CHAPTER 1
INTRODUCTION
N-linked glycosylation is an enzymatic process that takes place in eukarya, archaea, as well as
bacteria domains (1), where a preassembled oligosaccharide is covalently attached to the
asparagine side-chain nitrogen of proteins. Within eukaryotes, N-linked glycosylation has been
estimated to occur on approximately 50% of all proteins (2). Like phosphorylation, this common
form of protein modification can have dramatic effects on protein structure and function. Unlike
phosphorylation, which generally imparts an on/off effect, N-linked glycans allow for many
downstream effects due to the diversity of glycans employed (Figure 1-1) (3,4). The diversity of
glycan structure and the extensive enzyme machinery that is needed to produce this diversity
makes N-linked glycosylation and N-linked glycoproteins especially challenging and interesting
to study. This introduction will provide a brief background on N-linked glycosylation as it
occurs in eukaryotes and the bacterium Campylobacter jejuni, and its general effects on
glycoproteins.
HO
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HO HO
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Figure 1-1. Eukaryotic N-linked glycan in S. cerevisiae attached to the asparagine side chain of
the acceptor protein (5). Wavy lines represent the extension of the polypeptide.
1-1. N-linked glycosylation in eukaryotes
Eukaryotic N-linked glycosylation has been most extensively studied in the yeast system of
Saccharomyces cerevisiae (3,6). The process begins on the cytosolic surface of the endoplasmic
reticulum (ER) where a series of glycosyltransferases build up an oligosaccharide on a dolichyl
diphosphate-carrier using uridine diphosphate (UDP) and guanosine diphosphate (GDP)
activated sugars (Figure 1-2). Dolichols are a family of a-saturated polyisoprenols consisting of
14-17 isoprene units, which is embedded within the membrane bilayer (7). The glycan is
assembled to the point of a heptasaccharide of defined structure, consisting of two core N-
acetylglucosamine (GlcNAc) and five mannose (Man) residues in a branched structure (3).
Oligosaccharide
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Figure 1-2. The eukaryotic N-linked glycosylation pathway in S. cerevisiae. Following its
transfer to the acceptor protein, the tetradecasaccharide glycan undergoes additional processing
in the ER and the Golgi apparatus. GlcNAc = N-acetylglucosamine.
After this heptasaccharide is assembled, it is flipped from the cytosolic to the lumenal face of the
ER membrane by an ATP-independent, bi-directional, membrane-spanning flippase (8). Within
the ER, glycan assembly is continued by another series of glycosyltransferases, which work
sequentially to add on four additional branching Mans and three terminal glucoses (Glc) to form
the tetradecasaccharide "core" unit (Figure 1-1) (3). One important difference in this case is that
instead of using water soluble nucleotide-activated UDP-sugar or GDP-sugar donors, the
glycosyltransferases within the ER lumen use membrane-associated, dolichyl phosphate-bound
sugar donors.
Transfer of the tetradecasaccharide to protein occurs in the ER lumen. Potential glycoproteins
that are designated for the secretory pathway contain a signal sequence that is recognized by the
signal recognition particle (SRP), which directs the sequence to the translocation machinery for
transport across the ER membrane (9,10). The signal sequence is then cleaved by a dedicated
protease (11). At this point, the nascent protein interacts with the oligosaccharyltransferase
(OT), which takes the fully assembled tetradecasaccharide from the dolichyl diphosphate-carrier
and transfers it to the asparagine side chain of an acceptor protein within the consensus sequence
Asn-X-Ser/Thr where X can be any amino acid except for proline (12,13). This process occurs
as protein translation is taking place. Following this transfer, the glycan undergoes further
processing throughout the ER and the Golgi apparatus where additional glycosyltransferases and
glycosidases modify the glycan structure (4,14).
The S. cervisiae OT consists of at least eight membrane bound protein subunits, five of which are
essential for yeast viability (Figure 1-3) (12,13). Each of the subunits is highly hydrophobic and
many are themselves modified by N-linked glycans. This protein complex cannot be effectively
recombinantly overexpressed in Escherichia coli or in baculovirus-infected insect cells, and has
been found to be extremely difficult to purify. As a result, precise biochemical and biophysical
characterizations are very difficult to carry out. The chemistry that the OT catalyzes is quite
remarkable because it is capable of activating the nitrogen of the asparagine amide side chain
which is an extremely poor nucleophile. Currently, the molecular details of this reaction
mechanism remain uncertain. One possible mechanism involves the formation of an Asx-turn,
which would help protonate the carbonyl oxygen and allow an enzyme-mediated deprotonation
of the nitrogen to tautomerize the amide into a neutral nucleophilic imidol species (Figure 1-4).
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Figure 1-3. Subunit composition of the S. cerveisiae oligosaccharyltransferase complex (6).
The boxed subunits are essential for yeast viability. Only one of Ost6p or Ost3p is present in a
single OT complex.
Enzyme-BH+
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Figure 1-4. Proposed mechanism of the oligosaccharyltransferase.
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1-2. N-linked glycosylation in Campylobacterjejuni
For many years, N-linked glycosylation was thought to be unique to the eukarya and archaea
domains (1,6,15). Recently, C. jejuni became the first bacterium found to contain a general N-
linked protein glycosylation pathway (Pgl) (16,17). Although the enzymes and substrates are
different, the overall process shares many parallels with eukaryotic pathway in S. cerevisiae.
The Pgl pathway consists of a total of nine enzymes (Figure 1-5) (18). Three enzymes, PglF,
PglE, and PglD, function to biosynthesize the UDP-activated form of an unusually modified
sugar, 2,4-diacetamido-bacillosamine (bacillosamine) at the cytosolic face of the periplasmic
membrane. These three enzymes function as a dehydratase, an aminotransferase, and an
acetyltransferase, respectively, creating the necessary modifications to the UDP-N-
acetylglucosamine (UDP-GlcNAc) starting material.
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Figure 1-5. The prokaryotic N-linked glycosylation pathway in C. jejuni. GalNAc = N-
acetylgalacosamine; GlcNAc = N-acetylglucosamine; bacillosamine = 2,4-diacetamido-
bacillosamine.
Bacillosamine is the first sugar that is transferred to the polyisoprenol-carrier (18,19). The
carrier in this case is undecaprenol, an a-unsaturated polyisoprenol consisting of 11 isoprene
units, which is shorter than the eukaryotic dolichol, but still very hydrophobic and embedded
within the membrane. PglC is the glycosylphosphotransferase that transfers bacillosamine
phosphate onto undecaprenyl phosphate (19). This is followed by the actions of four more
glycosyltransferases, PglA, PglJ, PglH, and PglI which sequentially add five additional N-acetyl-
galactosamines (GalNAc) and one branching Glc to form the full heptasaccharide (Figure 1-6)
(20). Similar to the eukaryotic system, the polyisoprenyl diphosphate-linked heptasaccharide is
flipped by a flippase, PglK, across the membrane into the periplasm (21). Within the periplasm,
the heptasaccharide is transferred by the C. jejuni OT, PglB, from the undecaprenol-carrier to the
asparagine side chain of the acceptor protein (22,23). Unlike the eukaryotic system, no further
processing of the heptasaccharide is known to occur after it has been transferred to the protein
acceptor.
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Figure 1-6. C. jejuni N-linked glycan donor: undecaprenyl diphosphate-heptasaccharide.
Another major difference between C. jejuni pathway and the prototypic eukaryotic counterpart is
found in the OT structure. In C. jejuni, PglB consists of only a single membrane bound subunit
as opposed to the eight subunits in the eukaryotic complex. However, PglB shares sequence
homology and membrane topology with the Stt3p subunit of the S. cerevisiae OT, suggesting
that they have a similar function and are likely to operate by the same mechanism (22).
Advantageously, PglB and the other enzymes in the Pgl pathway can be recombinantly
overexpressed in E. coli (23). This makes PglB a much more promising target for mechanistic
and crystallographic studies than the eukaryotic OT. Although many archaeal systems also
possess single subunit OT, limited information is known about their glycan structure and
synthetic pathway (15). The Pgl pathway of C. jejuni overall provides a very useful model for
N-linked glycosylation because it has accessible substrates, a smaller number of enzymes, and is
relatively straightforward to express and purify.
1-3. The general effects of N-linked glycosylation
It is important to note that the N-linked glycan is fairly large in comparison to the protein to
which it is attached, especially considering that many proteins contain multiple glycosylation
sites. Each glycan may weigh up to 3 kDa and can extend 3 nm or more into solution (4). These
glycans are flexible, hydrated branched structures that may behave relatively independently of
the protein. The presence of this large hydrophilic appendages can have many different effects,
depending upon its location on the protein (4). N-linked glycans have been shown to improve
protein solubility by covering exposed hydrophobic patches on protein surfaces (24), and to
increase proteolytic stability by sterically blocking protease access (25). They have also been
known to modulate enzyme activity although the exact cause of this effect has not generalized
(26).
N-linked glycans are ideal tags for signaling because the chemistry of their glycosidic linkages
allows for incredible diversity and versatility in their structure, providing a large amount of
information within a localized space (4,27). Glycan are known to interact with many
carbohydrate-binding proteins called lectins through weak but cooperative binding. Many of
these lectins are involved in protein transport (28), antigen recognition (29), or as chaperones for
protein folding (30). Recognition of the N-linked oligosaccharide allows lectins to determine
protein localization, specific cell types, and whether it is properly folded. As the glycans are
processed in the ER and the Golgi complex, subtle modifications to the glycan structure allows
for adjustments in these interactions.
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Figure 1-7. Example of A) an Asx-turn and B) a p-turn. The curvy lines represent the
extension of the polypeptide.
In vitro and in silico studies have also revealed the ways in which the N-linked glycan can more
directly impact protein structure (31). Studies on glycopeptides reveal a dramatic
conformational change upon glycosylation from an extended Asx-turn to a more compact type 1
f-turn (Figure 1-7) (32). Surprisingly this structural change does not appear to arise from
hydrogen-bond interactions between the glycan and the peptide, but rather through steric
crowding or solvent-mediated effects (5). Furthermore, the effects of the glycan are heavily
dependent on the specific structure of the glycan. Substitution of the inner two GlcNAcs for
glucoses (33), and replacement of the native f-asparagine linkage to an a-linkage (34) both fail
to induce -turn formation. It has been proposed that the presence of an N-linked glycan in
critical locations within the protein may promote protein folding by restricting the dihedral
angles and the overall conformational space available to the local structure (31,35).
1-4. Dissertation objectives
Eukaryotic N-linked glycoproteins typically contain glycans of very heterogeneous structures
because of the many glycosyltransferases and glycosidases that are involved in their processing
(3). This structural diversity makes it very difficult to obtain homogeneously glycosylated
protein for biophysical studies. In Chapter 1, we describe a semi-synthetic approach to obtaining
N-linked glycoproteins with direct control over the glycan structure and site. Using this
approach we were able to synthesize a set of highly pure and homogeneously-glycosylated
proteins in milligram quantities.
Since N-linked glycosylation is a co-translational process in eukaryotic organisms, and occurs
before the protein has reached its native structure, it has long been implicated to have an effect
on protein folding (6). Many studies on glycopeptides have already shown that the presence of
the N-linked glycan can dramatically effect the peptide conformation (32). In Chapter 2, we
describe quantitative folding kinetic studies using the glycoproteins synthesized from the
previous chapter. We found that the presence of the glycan can result in distinct changes to both
the rate of protein folding and unfolding, and that the effect is highly specific to the local
structure of the glycosylation site.
Bacillosamine is a highly modified sugar in the C. jejuni N-linked glycosylation pathway (36).
As the first sugar transferred to the polyisoprenyl diphosphate-carrier, bacillosamine is part of
the substrates of every glycosyltransferase and the OT in the Pgl pathway. Since bacillosamine
is not commercially available and cannot be obtained in sufficient quantities within this
pathogenic bacterium, we describe in Chapter 3 a chemo-enzymatic synthesis to obtain this
unusual sugar. Access to large quantities of highly pure bacillosamine and its derivatives
(Figure 1-8) greatly facilitated our ability to probe many of the important enzymes within the
pathway.
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Figure 1-8. Structure of bacillosamine derivatives used in the study of the Pgl pathway.
In eukaryotic N-linked glycosylation, the OT transfers the glycan to the asparagine side chain of
the sequence Asn-X-Ser/Thr where X can be any amino acid other than proline (37). Using a
small library of peptides and a radiolabeled undecaprenol-linked glycan substrate made from our
newly synthesized UDP-bacillosamine, we describe in Chapter 4 the determination of the
minimum consensus glycosylation sequence for the C. jejuni OT, PglB. Interestingly, PglB
appears to contain additional sequence requirements beyond the three residue motif. By
systematically altering the amino acids at each residue, we were also able to determine the
optimal sequence for PglB.
The interaction between membrane-associated enzymes and their lipophilic substrates has not
been well understood. The polyisoprene can either play a simple physical role in anchoring the
glycan to the membrane where the enzymes act, or it may play a more specific chemical role in
substrate recognition. In Chapter 5, we describe the incorporation bacillosamine into substrates
with non-native polyisoprenols and the assays performed using these non-native substrates with
three enzymes from the C. jejuni pathway, each with different membrane topology. The non-
native polyisoprenols differed in their overall length, degree of unsaturation, and double bond
geometry. Probing the enzymes with these substrate analogues allowed us to derive insight into
the two possible roles for the polyisoprenes.
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CHAPTER 2
SEMI-SYNTHESIS OF IM7 GLYCOSYLATED-VARIANTS
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Although N-linked glycosylation is one of the most ubiquitous forms of protein modification (1),
and occurs on approximately 50% of all eukaryotic proteins (2), comparatively little is known
about how glycosylation affects the function and activity of proteins. In fact, less than 10% of
the protein crystal structures currently deposited in the Protein Data Bank contain N-linked
glycan chains (3). Among those structures the glycan is often disordered, with electron density
for only the first two or three glycan residues attached. The major cause of this disparity can be
attributed to the challenges encountered with obtaining homogeneously glycosylated protein
samples. This difficulty arises because, unlike nucleic acids and amino acids, carbohydrates are
not synthesized from a coding template. Instead, a group of glycosyltransferases and
glycosidases of varied activity and specificity work together to form and modify the glycan,
resulting in tremendous complexity and diversity in both glycan structure and site occupancy
(1,4). Recombinant expression in other organisms or even changes in growth and cultivation
conditions usually results in non-native or abhorrent glycosylation patterns (5,6). Chemistry can
potentially provide a solution to this problem.
Various chemical and chemoenzymatic techniques have been developed to address the need for
homogeneously glycosylated proteins (7-9). Each method has its inherent advantages and
limitations with regards to site selection and protein yield.
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Figure 2-1. Comparison of three chemical approaches to glycoprotein synthesis: A)
glycoprotein remodeling; B) semi-synthesis; and C) tRNA suppression.
Glycoprotein remodeling is one such method which begins with a heterogeneous sample of a
glycoprotein and uses specific glycosidases to cleave off the heterogeneous portions of the
glycan, usually leaving a common mono- or disaccharide (Figure 2-1A) (10,11). This truncated
glycan can then be elaborated with specific glycosyltransferases to form the desired glycan.
However, this method does not allow for site control and is therefore limited to only native
glycosylation sites. It cannot guarantee homogeneity in glycan site occupancy, as often not all
sites are 100% glycosylated in every protein. Furthermore, the glycosyltransferase reactions do
not always proceed to completion, resulting in a mixture of glycoforms that may be difficult to
separate chromatographically.
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In vivo tRNA suppression is another method of glycoprotein synthesis which has been developed
as a general strategy for incorporating unnatural amino acids into proteins through the use of the
amber stop codon (TAG) and an unnatural amber suppressing amino acyl tRNA(CUA) (Figure 2-
IC) (12,13). The main challenge of this method is the directed evolution of a tRNA synthetase
which can selectively acylate an amber codon tRNA(CUA) with the glycosylated amino acid.
Once that has been accomplished, this method allows for the site specific incorporation of the
glycan at any site within the protein (14,15). Currently, this method has been used for the
incorporation of P-GlcNAc-serine and B-GlcNAc-threonine into proteins expressed in
Escherichia coli (16). However, this method has not yet been demonstrated for the synthesis of
N-linked glycoproteins, most likely because the translation efficiency and yield of the
glycoprotein is often limiting and can only be empirically determined.
Currently, the most robust and general approach to obtaining N-linked glycoproteins is through a
semi-synthesis methodology using the expressed protein ligation (EPL) reaction (Figure 2-2)
(17,18). This method involves the synthesis of a portion of the protein as a glycopeptide using
solid phase peptide synthesis, which offers complete control of glycosylation site, as well as
useful yields in the multi-milligram range. The remaining protein is recombinantly expressed. If
the N-terminal peptide contains a C-terminal thioester and the C-terminal peptide contains an N-
terminal cysteine, the two peptides can be joined by a chemical ligation reaction, which
establishes a native amide bond between the two peptides.
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Figure 2-2. Native chemical ligation reaction mechanism (17).
The requirement for a cysteine residue at the site of ligation can be met by simply incorporating
a cysteine point mutation at a site that does not impact protein function and structure, or
alternatively a cysteine can be transiently incorporated to facilitate the EPL reaction and then
chemically removed following the ligation, for example through Raney nickel desulfurization
(19,20). The main advantages to semi-synthesis are the control of glycosylation site, the general
applicability to all proteins, and the superior yield in comparison to other methods.
2-1. Semi-synthetic strategy of Im7 glyco-variants
For our current study we have developed a semi-synthetic strategy to obtain homogeneously
glycosylated variants of a full length protein in order to study the effects of N-linked
glycosylation on protein folding kinetics. We have chosen a small model protein of four helices
and 87 amino acids called immunity protein 7 (Im7). Im7 is a bacterial protein that functions as
a binding partner for the bacterial toxin protein colicin E7 (Figure 2-3) (21,22). Both Im7 and
colicin E7 are produced from the same plasmid, where Im7 protects the organism from the
cytotoxic properties of E7 prior to its secretion. Im7 is an ideal model protein for our study
because it has a well-characterized folding mechanism, and it lacks disulfide bonds, cis-proline
amide linkages, and prosthetic groups that can complicate folding kinetics (23). Although Im7
does not contain any native glycosylation sites, the careful selection and introduction of glycans
within various secondary structural motifs within this model protein can potentially reveal a
great deal about the general effects of N-linked glycosylation. While the thermodynamic effects
of N-linked glycosylation have been studied in peptide model systems (3,24,25), to our
knowledge this will be the first systematic study aimed at a quantitative characterization of the
folding kinetics of a full length homogeneously glycosylated protein.
Figure 2-3. Co-crystal structures of immunity protein Im7 (dark) and collicin E7 (blue) in
ribbon representation from RCSB Protein Data Bank (pdb code 7CEI).
In collaboration with Professor Sheena Radford's lab at the University of Leeds, we selected
seven sites of interest within the first and last 28 amino acids (Figure 2-4). We limited the sites
to solvent exposed residues in order to minimize any obvious steric clashes that would prevent
the protein from folding to its native structure. Among the seven selected glycosylation sites,
two are located within the middle of a helix, two are located near the end of a helix, and three are
located within loop regions of different topology. This range of glycosylation sites will allow us
to quantitatively determine whether the effects of N-linked glycosylation are general or specific
to the local secondary structure.
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Figure 2-4. Ribbon diagram of lm7 (pdb code 1AYI) with ligation (dark) and glycosylation
(blue) sites highlighted with spacefill side-chain representation. Amino acid sequence is listed
below with the four helices marked by boxes.
Figure 2-5. The tetradecasaccharide (Glc2Man 9GlcNAc 2) from Saccharomyces cerevisiae
attached to the asparagine side chain of the acceptor protein. The chitobiose disaccharide, found
in all eukaryotic N-linked glycans is highlighted in blue. Wavey lines indicate the extension of
the polypeptide chain. Structure drawing adapted from (24).
In eukaryotic N-linked glycosylation, a tetradecasaccharide (Glc2Man9GlcNAc2, Figure 2-5) is
initially transferred to proteins, followed by post-translational processing in the ER and the Golgi
apparatus where significant changes in the glycan structure accumulate (1,4). Despite these
modifications, the disaccharide that is attached to the asparagine, GlcNAc-P-1,4-GlcNAc-3,
often referred to as chitobiose, remains unchanged. Using various glycopeptides, previous
studies from our lab have demonstrated significant structural effects on the peptide backbone
originate from the chitobiose moiety, while the distal sugars only serve to amplify the initial
effect (26,27). Interestingly, this disaccharide alone is capable of inducing the formation of a
compact beta-turn (26,28). Since the chitobiose disaccharide is common to all N-linked
glycoproteins and since it displays a significant effect on the local peptide structure, we used this
truncated disaccharide as the model glycan in the Im7 glycoprotein assembly.
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Figure 2-6. Im7 glyco-variants semi-synthetic strategy. Each variant consists of a
glycopeptides made by solid phase peptide synthesis and a larger peptide made by expression.
EPL = expressed protein ligation.
The semi-synthetic strategy we employ differs depending on whether the glycosylation site is
near the N- or C-terminus of the protein (Figure 2-6). In both cases, the glycopeptide was
synthesized by solid phase peptide synthesis, while the two larger peptides were both
recombinantly expressed with intein fusion tags from the commercially available IMPACT-
system (29) in order to incorporate the necessary N-terminal cysteine or the C-terminal thioester.
A cysteine was introduced at the A29C position to accommodate the N-terminal glycoproteins,
and another at the D59C position to accommodate the C-terminal glycoproteins. Both cysteines
were chosen to occupy sites that allow their side chains to be solvent exposed and were not
expected to form inter-residue contacts in the native state. Since they were not expected to
s
perturb the structure or folding of the overall protein, the cysteine residues were not removed
after ligation. For each corresponding Im7 glyco-variant, a non-glyco pseudo-wildtype was also
prepared, which contained both the cysteine mutation as well as the non-glycosylated asparagine.
Therefore, the direct effects of the glycan can be determined by comparing the glyco-variant
with the pseudo-wildtype control.
2-2. Synthesis of the protected Fmoc-Asn(chitobiose-TBDMSs)-OH building block
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Figure 2-7. Synthesis of Fmoc-Asn(chitobiose-TBDMSs)-OH building block.
Synthesis of the protected building block was carried out according to a previously developed
protocol from our lab (Figure 2-7) (30). Briefly, the chitobiose disaccharide was produced by
enzymatic degradation of chitin using a commercially available chitinase. The chitobiose was
then aminated at the anomeric position by the Likhosherstov method using ammonium
carbamate in methanol (31). The resulting glycosylamine was precipitated and immediately
coupled to the acid side chain of the Fmoc-Asp-OAll amino acid. Each hydroxyl group of the
chitobiose was silyl protected using TBDMS-OTf (tert-butyldimethylsilyltrifluoromethane
sulfonate). Final deprotection of the allyl group resulted in the desired building block product in
a form compatible with standard Fmoc-based solid-phase peptide synthesis. The key
improvement of this synthesis over previous methods was the Likhosherstov amination (31),
which is stereospecific for the beta-glycosylamine, since the alpha-glycosylamine is not
biologically relevant (30).
2-3. Synthesis of the Im7 C59-G87 glycopeptides and the Im7M1-A28 glycopeptide thioesters
The Im 7 MI-A28 and Im7C59-G8s7 glycopeptides (Figure 2-8) were synthesized by solid phase
peptide synthesis (SPPS) using standard Fmoc-based conditions with 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramnethyluronium hexafluorophosphate and hydroxybenzotriazole (HBTU and HOBt)
as the primary coupling reagents. However, 7-azabenzotriazol- 1-yloxy-
tris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP) was used for the coupling of the
Asn-chitobiose building block in order to accommodate the steric demands imposed by this
bulky amino acid (32). The highly acid-labile carboxy-trityl TGT resin was used as the solid
support. In the synthesis of lm7M1-A28 glycopeptide thioester, this resin selection played a critical
role by allowing the completed peptide to be cleaved from the resin under mild acidic conditions
with all the side chain protecting groups of the peptide intact. The free C-terminal acid can then
be converted into a thioester through chemical synthesis (33).
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Figure 2-9. Intein cleavage mechanism and the production of the lm7c29-G87 peptide.
Expression of peptides containing an amino acid other than methionine at the N-terminus can be
achieved using a cleavable recombinant expression construct. In this case we used the
[M + 3H]+
m/e
Im7 (C29-G87) expressed peptide
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commercially available pTWIN1 plasmid from New England Biolabs IMPACT-system, which
produced a construct consisting of a chitin binding domain for affinity purification, an
engineered pH-controlled intein, followed by the desired protein (Figure 2-9). Purification of
this construct was carried out at pH 8.5 (34-36). Once the construct had been bound to the chitin
resin and thoroughly washed, it was incubated overnight at pH 6, which caused the intein to self-
cleave, releasing the product with any desired N-terminal amino acid -- in this case a cysteine
(Figure 2-10). The eluted Im7C29-G78 peptide was further purified and desalted by reverse phase
HPLC (Figure 2-11), aliquoted, and lyophilized for storage. Not only does this construct allow
for the expression of a protein with a non-methionine N-terminal amino acid, it was also believed
to help solubilize truncated proteins that have exposed hydrophobic core residues and reduce
their aggregation (36).
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Figure 2-10. SDS-PAGE gel of Im7c29G87 purification. Lane 1: gel ladder; Lane 2: cell lysate
after dialysis refolding; Lane 3: flow through chitin column; Lane 4-6: wash with buffer pH =
8.5; Lane 7-8: elution with buffer pH = 6 after 12 hour incubation.
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Figure 2-11. lm7C29-G87 peptide:
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Figure 2-12. Intein cleavage mechanism and the production of the Im7 M1-S58 peptide.
Expression of the Im 7M-s58 peptide thioester was also carried out using intein technology from
the pTWIN1 plasmid from New England Biolabs.
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2-4. Expression of the Im7 l-S58 peptide thioester.
In this case a construct was produced,
consisting of the desired peptide, an engineered partially functional intein, followed by the chitin
binding domain for affifity purification (Figure 2-12) (34,35). The intein in this construct
contained a cysteine to alanine mutation which caused it to stop the cleavage mechanism after
the initial rearrangement, This left a thioester linkage between the desired peptide and the intein,
which allowed the desired peptide to be liberated as a free thioester through incubation with a
high solution concentration of free thiol (Figure 2-13) (35).
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Figure 2-13. SDS-PAGE gel of Im7 M-ss58 purification. Lane 1: gel ladder; Lane 2: cell lysate;
Lane 3: flow through Ni-NTA column; Lane 4: Ni-NTA column wash; Lane 5: Ni-NTA
elution; Lane 6: MESNA 8 hour incubation; Lane 7: flow through chitin column.
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Figure 2-14. Im7 Ml-S58 peptide thioester: A) Reverse phase preparative C18 HPLC profile at 228
nm and B) corresponding ESI mass spectra.
2-6. Native chemical ligation
Ligation of the synthetic peptide with the corresponding expressed peptide was carried out under
identical conditions for both the N-terminal glyco-variants as well as the C-terminal ones. Both
ligation sites were chosen with efficiency in mind, avoiding residues with large or branched side
chains in order to minimize steric hindrance during ligation. As a result, all ligations were
successfully carried out under native conditions with approximately 80% yield relative to the
limiting glycopeptides (32). The full length Im7 product can be efficiently purified from the
peptide starting materials by preparative C18 reverse phase HPLC (Figure 2-15). Although the
conditions of the HPLC no doubt caused the protein to denature, the robust quality of Im7
allowed it to successfully refold into its native structure when returned to a neutral aqueous
buffer.
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Figure 2-15. Full length ligated Im7 A29C/V27NGlyco protein: A) Reverse phase preparative C 18
HPLC profile at 228 nm and B) corresponding ESI mass spectra. It is not clear why the
expressed peptide has two elution peaks, although one possibility is that one is a monomer and
the other is a disulfide dimer.
2-7. Expression of the non-glyco pseudo-wildtype Im7 controls
For each glyco-variant, a corresponding non-glyco pseudo-wildtype Im7 control was produced
through bacterial expression. Using site direct mutagenesis, each pseudo-wildtype included the
ligation cysteine mutation at either position 29 or 59, as well as the asparagine mutation if the
glycosylation site is at a site that was not originally an asparagine. Therefore, each glyco-variant
of Im7 differed from its pseudo-wildtype only by the presence of the chitobiose disaccharide.
When directly compared, each Im7 pair should reveal the effect of the glycan alone.
2-8. Characterization of Im7 variants
In total, approximately 6-12 mg of each Im7 glyco-variant was produced using our semi-
synthetic strategy, along with more than 20 mg of each corresponding pseudo-wildtypes using
site directed mutagenesis. The purity and structural attributes of each variant were thoroughly
assessed prior to folding studies. Electrospray-ionization mass spectrometry established the
mass of each variant to be consistent with expected values. Each glyco-variant differed from the
non-glyco-variant by precisely the mass of the glycan moiety. Furthermore, no major extraneous
peaks were observed in the HPLC or mass spectrometry analysis. SDS-PAGE electrophoresis
revealed each sample to be greater than 95% pure. Close inspection of each lane of the gel
loaded with the glyco-variant did not indicate the presence of the ligation starting material or the
deglycosylated protein.
Circular dichroism spectroscopy was used to compare the secondary structures of each protein
(Figure 2-16). Since Im7 contained four helices, the signal at 208 and 222 nm is especially
indicative of its fold. Within error, we did not find the glycan nor the mutations incorporated in
our new constructs to significantly alter the helical content of Im7. Although this does not offer
information on the tertiary structure of Im7, it is consistent with our expectation that each variant
fold to the same native state (32,37).
To further investigate the structure of the folded state of each variant, we compared the
fluorescence of W75 within Im7 under native and denaturing conditions of 8 M urea (Figure 2-
17). Residue W75 is highly fluorescent in the unfolded state. However, in the native state, it is
placed in close proximity to H47 which quenches its fluorescence (32,37). The same degree of
fluorescence quenching observed for each Im7 further suggested that each protein is folded to the
same native state since this quenching phenomenon is highly dependent on the relative positions
of W75 and H47.
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Figure 2-16. Circular dichroism spectra of Im7 variants.
1.0 - A29C / N5-Glyco OM 1.0-
/- - A29C / N5-Glyco 8M
0.8 \ - A29C OM 0.8-\ -- A29C 8M
0.6 \ 0.6-
0.4 D O4 -
0.2- - 0.2 -
0.0 - 0.0-
300 320 340 360 380 400 420 440 3C
Wavelength (nm)
- - A29C / K20N-Glyco OM
S t - - A29C / K20N-Glyco 8M
S - A29C / K20N OM
S- A29CIK20N 8MV
i\
A \
320 340
0.2-
0.0-
3
I I I 1 1
360 380 400 420 440
Wavelength (nm)
- -- D59C / N60-Glyco OM
S- - D59C / N60-Glyco 8M
S L, -- D59C OM
/ -- D59C 8M
320 340
/
- A29C / A13N-Glyco OM
- A29C I/A13N-Glyco 8M
S - A29C/A13N OM
- - A29C/ A13N 8M
-A
- N,
320 340 360 380 400 420 440
Wavelength (nm)
- A29C / V27N-Glyco OM
S - - A29C I/ V27N-Glyco 8M
S A29C / V27N OM
/ -- A29C/ V27N 8M
, N
I 340
320 340 360 380 400 420 440
Wavelength (nm)
-- D59C / K73N-Glyco OM
- - D59C / K73N-Glyco 8M
, - D59C / K73N OM
/ \ - D59C/ K73N 8M
, \\
,C'
,N
.300
300360 380 400 420 440
Wavelength (nm)
320 340
320 340 360 380 400 420 440
Wavelength (nm)
, -- D59C / A78N-Glyco OM
- - D59C / A78N-Glyco 8M
S -- D59C / A78N OM
' - - D59C / A78N 8M
/ \
iv
ivC
320 340
320 340 360 380 4
Wavelength (nm)
420 440
Figure 2-17. Fluorescence emission spectra of Im7 variants in 0 and 8 M urea at ma = 280 nm.
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Conclusion
In conclusion, we have developed a general and robust strategy for the semi-synthesis of
homogeneously glycosylated Im7 variants. Our strategy involved the ligation of a synthetic
glycopeptide with a larger recombinantly expressed peptide. This approach allowed us to
incorporate a biologically relevant disaccharide anywhere within the first or last 28 amino acids
of our protein, and prepare the proteins in multi-milligram quantities of greater than 95% purity.
We applied this strategy to access seven glyco-Im7 variants, placing the glycan at seven
carefully selected locations representing a survey of different secondary structures from helices
to loops. Circular dichroism and fluorescence spectroscopy was used to verify that the mutations
and glycans have not significantly changed the native folded state of Im7. Most importantly, we
now have access to enough protein to carry out stopped-flow fluorescence spectrometry
experiments to quantitatively measure the effects of the glycan on the kinetics of protein folding.
Our semi-synthetic strategy represents one of the most general methods of glycoprotein synthesis
currently reported. It allowed for the production of glycoprotein in sufficient quantities and to a
degree of purity and homogeneity to allow the use of various biophysical techniques for their
detailed characterization. Successful application of this strategy for the synthesis of other
glycoproteins may help to address our current limitations in the study of protein glycosylation.
Experimental
Synthesis of Fmoc-Asn(Chitobiose-TBDMS )-OH.
Synthesis of the Fmoc-Asn(Chitobiose-TBDMS 5)-OH building block was carried out following
literature protocol (30) starting from commercially available crab shell chitin. The critical step
in the synthesis involves the drying of the isolated crude amino chitobiose prior to coupling to
the Fmoc-Asp(OH)-OAll amino acid. Excessive drying causes degradation, while inadequate
drying leaves residual methanol which interferes with the subsequent coupling reaction.
Sequence, numbering, anrd structure of the Im7 construct.
MEHHHHHH E2LKNSISDY TEAEFVQLLK EIEKENVAAT DDVLDVLLEH
FVKITEHPDG TDLIYYPSDN RDDSPEGIVK EIKEWRAANG
KPGFKQG
The residue numbers listed in this thesis are those of the untagged protein, where (E2)
corresponds to the second residue of the protein (38). The crystal structure of Im7 protein can be
found at the RCSB Protein Data Bank code 1AYI (22).
Synthesis and purification of the Im7c59-G87 glycopeptides.
The Im7C59-G87 glycopeptides were synthesized on Fmoc-Gly-NovaSyn TGT resin
(NovaBiochem) starting on an ABI 431A automated peptide synthesizer (Applied Biosystems)
using standard Fmoc (9-fluoenylmethoxycarbonyl) coupling procedures. Fmoc deprotection was
carried out using 20% 4-methylpiperidine in NMP (1-methyl-2-pyrrolidinone, Aldrich). Double
coupling for each amino acid was carried out using 4 eq. Fmoc-amino acid (GenScript or
NovaBioChem) per eq. resin, 4 eq. HOBt (N-Hydroxybenzotriazole, GenScript), and 4 eq.
HBTU (2-(1HBenzotriazole- 1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, GenScript)
as activating agents, with DIPEA (diisopropylethylamine, Aldrich) in NMP, for one hour at room
temperature. Acetic anhydride capping was carried out to terminate unreacted free amines after
each amino acid.
Coupling of the Fmoc-Asn(Chitobiose-TBDMS 5)-OH building block, as well as the 2 subsequent
amino acids, were carried out by hand using 4 eq. of the Fmoc-amino acid, and 4 eq. PyAOP (7-
azabenzotriazol-1-yloxy-tris(pyrrolidino)phosphonium hexafluorophosphate, GenScript) as the
coupling agent, with DIPEA in DMF (dimethylformamide, Aldrich). TNBS (2,4,6-
trinitrobenzenesulfonic acid) was used to check for the presence of a free amino terminus for
completion of each reaction.
Cleavage from the resin and global deprotection was carried out using cleavage cocktail K [82%
TFA (trifluoroacetic acid), 3% EDT (1,2 ethanedithiol), 5% thioanisol, 5% phenol, and 5%
water], shaking for 2 hours at room temperature. The desired glycopeptide was precipitated in
cold diethyl ether, purified by preparative reverse phase C18 HPLC, confirmed by electrospray
ionization mass spectrometry (ESI-MS) to be within 1 Da of expected mass, checked by
Coomassie staining of SDS-PAGE to be >95% pure, and lyophilized for storage.
Synthesis and purification of the Im7M1uA28 glycopeptide thioester.
The Im7Ma-A28 glycopeptides were synthesized on Fmoc-Ala-NovaSyn TGT resin
(NovaBiochemn) using the same protocol as described for the Im 7 C59-G87 peptide above. When
the glycopeptide was completed, it was cleaved from the resin using cleavage cocktail A [0.5%
TFA, 99.5% dichloromethane], shaking for 2 hours at room temperature, resulting in a peptide
with a free carboxyl terminus and fully intact side chain protecting groups. This peptide was
dried under reduced pressure, washed with diethyl ether, redissolved in anhydrous DMF, and
treated with 10 eq. of benzyl mercaptan (Aldrich), 3 eq. of PyBOP (benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate, GenScript), followed by 3 eq. of DIPEA.
The mixture was stirred for 8 hours under N2. The DMF solvent was removed by rotoary
evaporation under high vacuum, and the resulting yellow oil is treated for 2 hours at room
temperature with cleavage cocktail K for global deprotection. The desired glycopeptide thioester
were precipitated in cold diethyl ether, purified by preparative reverse phase C18 HPLC,
confirmed by ESI-MS to be within 1 Da of expected mass, check by Coomassie staining of SDS-
PAGE to be >95% pure, and lyophilized for storage.
Mutagenesis of lm7 non-glvco pseudo-wildtype variants.
A pTrc(Im7)-99A vector was provided by Professor Sheena Radford from the University of
Leeds, encoding the native Im7 protein with an N-terminal hexa-histidine tag described
elsewhere (38). Introduction of point mutations in Im7 was performed using the Quikchange
mutagenesis kit (Stratagene). All variants were sequenced to ensure that the gene contained the
desired change.
Expression and purification of Im7 non-glyco pseudo-wildtype variants.
Starting from a 5 mL overnight culture, BL21(DE3) cells (Stratagene) expressing Im7 variants
were grown at 37 'C in 1 L of LB broth containing carbenicillin antibiotic to an OD600 of 0.6-0.8.
At that point protein production was induced by the addition of 1 mM IPTG (isopropyl-P-D-
thiogalactopyranoside). After 3 hours, the cells were harvested by centrifugation (7,500 x g) for
30 min, washed once with a 0.9% NaCl solution, centrifuged again (7,500 x g) for 30 min, and
the cell pellet was frozen at -80 oC until needed.
All purifications steps were performed at 4 oC. Cell pellets containing the Im7 variants were
thawed and resuspended in 5% of the original culture volume in buffer L [50 mM Tris-acetate, 5
mM imidazole, pH 8]. The cells were lysed by sonication, followed by centrifugation (142,400 x
g) for 1 h to remove cellular debris and membrane proteins. The supernatant was slowly applied
to a column containing Ni-NTA agarose equilibrated with buffer L. After washing with 5
column volumes of buffer L, the purified protein was eluted with buffer E [50 mM Tris-acetate,
250 mM imidazole, pH 8]. Fractions containing a significant amount of desired protein were
combined and purified by preparative reverse phase C18 HPLC, confirmed by ESI-MS to be
within 1 Da of expected mass, checked by Coomassie staining of SDS-PAGE to be >95% pure,
and lyophilized for storage.
Cloning of Intein Im 7c29 87 construct.
Starting from the pTrc(Im7A29c)-99A vector, the Im7C29-G87 peptide was amplified using primers
which engineered 5' Sapi and 3' BamHl restriction sites and the Vent polymerase (New
England Biolabs) under standard conditions described by the manufacturer for 30 cycles. Both
the amplicons and the IMPACT pTWIN1 vector was doubly digested with Sapl and BamH1
restriction enzymes (New England Biolabs), fractionalized by agarose gel electrophoresis, and
purified with the QlAquick gel extraction kit (Qiagen). Ligations were conducted with the T4
DNA ligase kit (Promega) for 1.5 hours at 16 oC. The ligation product was transformed into a
competent DH5a strain of E. coli (Invitrogen), spread on plates containing LB media and
carbanicillin. The desired pTWIN 1(Im 7c29-G87) plasmid from colonies formed on the plates were
isolated, verified by sequencing at the MIT CCR HHMI Biopolymers Lab, and transformed into
a competent BL21(DE3) strain of E. coli for overexpression.
Expression and purification of Im7 C29-G87 peptide.
Starting from a 5 mL overnight culture, BL21(DE3) cells (Stratagene) expressing
pTWIN1(Im7c29_G87) were grown at 37 'C in LB broth containing carbenicillin antibiotic to an
OD60oo of 0.6-0.8. At that point protein production was induced by the addition of I mM IPTG
(isopropyl-3-D-thiogalactopyranoside). Expression at this temperature leads to the
overexpressed construct to form inclusion bodies. After 3 hours, the cells were harvested by
centrifugation (7,500 x g) for 30 min, washed once with a 0.9% NaCI solution, centrifuged again
(7,500 x g) for 30 min, and the cell pellet was frozen at -80 oC until needed.
All purifications steps were performed at 4 'C. Cell pellets containing the Im 7 C29-G87 construct
were thawed and resuspended in 5% of the original culture volume in buffer M [20 mM Tris-
HC1, 500 mM NaC1, pH 8.5]. The cells were lysed by sonication, followed by centrifugation
(142,400 x g) for 1 hour to precipitate the cellular debris and inclusion bodies containing the
desired construct. The isolated pellet was homogenized into 10% of the original culture volume
in buffer G [20 mM Tris-HC1, 500 mM NaCl, 7 M guanidinium chloride, pH 8] and left stirring
for 1 hour. The cellular debris was removed from the dissolved protein by centrifugation
(142,400 x g) for 1 hour. The supernatant was dialyzed into refolding buffers R-1/2/3/4/5/6 [20
mM Tris-HC1, 500 mM NaCi, 8/6/4/2/0/0 M urea, 1 mM DTT (dithiothreitol), pH 8.5] which
contained sequentially dilute concentrations of urea, for 12 hours in each buffer. The dialysis
product was then added to a column of chitin resin (New England Biolabs), of 1% the original
culture volume and prewashed with buffer R-6, at a flow rate of 0.5 mL/min. The column was
washed with 15 column volumes of buffer R-6 and then incubated in buffer C [20 mM Tris-HC1,
1 mM DTT, pH 6.0] at room temperature for 16 hours to induce intein cleavage. The column is
then washed with buffer C until all protein products have been eluted. The isolated Im 7c29-G87
peptide is then further purified by preparative reverse phase C18 HPLC, confirmed by ESI-MS to
be within 1 Da of expected mass, checked by Coomassie staining of SDS-PAGE to be >95%
pure, and lyophilized for storage. A 1 liter expression typically yields approximately 4-5 mg of
desired product.
Cloning of Im 7M-ss8 Intein construct.
Chitin
Starting from the pTrc(im7)-99A vector, the Im7M-ss58 peptide was amplified using primers
which engineered 5' Ndel and 3' Sapl restriction sites and the pFu Turbo polymerase
(Stratagene) under standard conditions described by the manufacturer. Both the amplicons and
the IMPACT pTWIN1 vector were doubly digested with Ndel and Sapl restriction enzymes
(New England Biolabs), fractionalized by agarose gel electrophoresis, and purified with the
QIAquick gel extraction kit (Qiagen). Ligations were conducted with the T4 DNA ligase kit
(Promega) for 15 min at room temperature. The ligation product was transformed into a
competent DH5a strain of E. coli (Invitrogen), spread on plates containing LB media and
carbanicillin. The desired pTWIN1(Im7Ml-S58) plasmid from colonies formed on the plates were
isolated, verified by sequencing at the MIT CCR HHMI Biopolymers Lab, and transformed into
a competent BL21(DE3) strain of E. coli for overexpression.
Expression and purification of lm7Ml-s5 peptide thioester.
Starting from a 5 mL overnight culture, BL21(DE3) cells (Stratagene) expressing
pTWINI(Im7MI-s 58) were grown at 37 'C in LB broth containing carbenicillin antibiotic to an
OD600 of 0.6-0.8. At that point the temperature was lowered to 16 'C and protein production was
induced by the addition of 1 mM IPTG for 16 hours. The cells were harvested by centrifugation
(7,500 x g) for 30 min, washed once with a 0.9% NaCl solution, centrifuged again (7,500 x g) for
30 min, and the cell pellet was frozen at -80C until needed.
All purifications steps were performed at 4 'C. Cell pellets containing the Im 7 Ml-S5s construct
were thawed and resuspended in 2.5% of the original culture volume in buffer N [20 mM
HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid), pH 8]. The cells were lysed by
sonication, followed by centrifugation (142,400 x g) for 1 hour to remove cellular debris and
membrane proteins. The supernatant was slowly applied to a column containing Ni-NTA
agarose equilibrated with buffer L. After washing with 4 column volumes of buffer W [20 mM
HEPES, pH 6], the purified construct was eluted with 25 mL of buffer D [20 mM HEPES, 200
mM imidazole, pH 6]. To the elution was added 2 g MESNA (sodium 2-
mercaptoethanesulfonate) and incubated for 8 hours at 37 'C followed by 8 hours at 4 oC to
cleave the intein and release the Im7Ml-S58 peptide thioester. To remove the CBD-intein (chitin
binding domain), the mixture was then applied to a column of chitin resin of 0.5% the original
culture volume. The flow through containing the desired Im 7 1-ss58 peptide thioester was
collected and purified by preparative reverse phase C18 HPLC, confirmed by ESI-MS to be
within 1 Da of expected mass, checked by Coomassie staining of SDS-PAGE to be >95%, and
lyophilized for storage. A 1 liter expression typically yields approximately 10 mg of desired
product.
Native chemical ligation.
The appropriate lyophilized peptide pairs were dissolved in buffer P [100 mM sodium phosphate,
pH 7] and quantified by UV (X = 280 nm, c = 9530 M-1 cm-1). The synthetic glycopeptides was
made to a concentration of 2 mM, while the expressed peptide was used in excess at 3 mM. To
initiate the ligation reaction, an equal volume mixture of the appropriate peptides was mixed,
followed by the addition of 2% benzyl metcaptan and 2% benzenelthiol. After 16 hours of
shaking at room temperature, the precipitated thiols were removed by centrifugation (40,000 x g)
and the full length Im7 variant was applied to a preparative reverse phase C18 HPLC, confirmed
by ESI-MS to be within 1 Da of expected mass, checked by Coomassie staining of SDS-PAGE
to be >95% pure and lyophilized for storage. By HPLC peak area, the typical yield for the
ligation reaction was 80%.
Circular dichroism evaluation of Im7 variants.
Far-UV circular dichroism (CD) spectra were acquired on an Aviv Model 202 spectropolarimeter
(Aviv Biomedical) using a 1 mm path length cell and a protein concentration of 250 [tg/mL in
buffer U [50 mM sodium phosphate, 400 mM sodium sulfate, 1 mM EDTA
(ethylenediaminetetraacetic acid), pH 7] at 250C.
Fluorescence evaluation of lm7 variants.
Fluorescence emission spectra of each Im7 variants were measured using a Photon Technology
International Fluorimeter (Ford, West Sussex, UK). For spectra of native and denatured Im7
variants each protein was dissolved in native buffer U or denatured buffer U with 8 M urea to a
protein concentration of approximately 50 pM. Excitation slit widths were set to 2 nm, emission
slit widths were adjusted for protein concentration. Each spectrum was recorded from 270 nm to
450 nm in 1 nm increments, using an excitation wavelength of 280 nm. Spectra of all denatured
states were assumed to have the same maximum intensity at 350 nm. The spectra of each native
protein were normalized to the intensity of the respective denatured state, allowing direct
comparison of the fluorescence intensity between variants.
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CHAPTER 3
EFFECT OF GLYCOSYLATION ON IM7 FOLDING KINETICS
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In 1961, Anfinsen and co-workers demonstrated that denatured ribonuclease A (RNase A)
spontaneously refolds to its native state without the requirement for other biological machinery
(1), leading to the understanding that the precise three-dimensional structure of a protein is
encoded within its amino acid sequence (2). Since this discovery, much effort has been devoted
to understanding the mechanism of protein folding, including the major thermodynamic and
kinetic forces that drive this process and the possibility of predicting structure from sequence
(3,4). In addition to these important questions, the study of protein folding has also been
motivated by the realization that the misfolding and aggregation of particular proteins is
associated with a wide range of debilitating human diseases (5,6), such as cystic fibrosis (7),
cataracts (8), bovine spongiform encephalopathy (mad-cow) (9), type II diabetes (10), and
Alzheimers and Parkinsons diseases (11).
Unlike most types of protein modification, N-linked glycosylation in eukaryotics cells is a co-
translational process that occurs as a nascent protein is translocated into the lumen of the
endoplasmic reticulum (ER) before the entire protein has been biosynthesized by the ribosome
(12). Since the glycan is installed on the acceptor protein before the protein reaches its native
structure, N-linked glycosylation has long been implicated in the protein folding process.
Indeed, there have been numerous examples in which glycoproteins are unable to attain their
native structures without the appropriate N-linked glycan, a situation often found when
mammalian glycoproteins are expressed in Escherichia coli (13,14). Since approximately 50%
of all eukaryotic proteins carry N-linked glycans (15), it is important to understand the specific
effects of the N-linked glycan on the protein folding process. Our current understanding of N-
linked glycosylation reveals two different general mechanisms through which the glycans can
influence protein folding: through interactions with chaperone proteins and through direct
structural effects on the local polypeptide backbone.
In vivo studies have found numerous quality controls and folding efficiency enhancement
mechanisms within the ER that are N-linked glycan dependent. Many chaperone proteins within
the ER are lectins that recognize and bind to specific features of the N-glycan on newly
synthesized proteins (16). One well studied example of N-glycan mediated quality control
involves the calnexin / calreticulin (CNX / CRT) pair of ER resident lectins, which bind to and
facilitate the folding of proteins with the monoglucosylated glycan GlcaMan 9GlcNAc 2 (17). The
progress of the folding is checked by a glycosidase and glycosyltransferase pair, which removes
the single remaining glucose if the protein is folded, or retains the glucose if the protein is still
unfolded and requires further interaction with CNX and CRT. Glycoproteins undergoing futile
folding attempts are trimmed of their terminal mannose residues to Man8GlcNAc2 or
MansGlcNAc 2 by a-1,2-mannosidases within the ER, which target these misfolded proteins for
degradation. The specific structure of the N-glycan provides a handle for the binding of
chaperones and allows them to sense whether the glycoprotein is properly folded (17).
Both in vitro and in silico studies also point toward a more direct mechanism through which N-
linked glycosylation can influence protein folding. The tetradecasaccharide glycan initially
transferred to the acceptor protein is a large and hydrophilic moiety comparable in volume and
surface area to the protein itself, especially since many proteins carry multiple glycans. Studies
on glycopeptides reveal a dramatic conformational change from an extended Asx-turn to a more
compactly folded type 1 Pf-turn upon glycosylation (Figure 3-1) (18). This structural change
does not appear to arise from hydrogen bond interactions between the glycan and the peptide, but
rather through steric crowding or solvent-mediated effects (19). Furthermore, the effects of the
glycan are heavily dependent on its specific structure. Substitution of the inner two N-acetyl
glucosamines with glucose (20), as well as changing the native f-asparagine linkage to an a-
linkage (21) both fail to induce P-turn turn formation. It has been proposed that the presence of
an N-linked glycan in critical locations within the protein may promote folding by restricting the
rotational backbone dihedral angles and overall conformational space available to the local
structure (22,23).
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Figure 3-1. Example of A) an Asx-turn and B) a P-turn. The curvy lines represent the
extension of the polypeptide.
Although the structural and thermodynamic effects of N-linked glycans on protein structure have
been studied in many systems, there is comparatively little information on how N-linked glycans
affect the kinetics of protein folding. This is primarily because of the difficulties in obtaining
homogeneously glycosylated protein samples (24). Naturally glycosylated proteins have been
isolated and used to demonstrate that refolding is much more efficient compared to the apo form.
For example when the N-linked glycoprotein ECorL from Erythrina corallodendron was
refolded from 6 M urea the recovery was 80-90% while the apo form yielded only 10-20% from
the same refolding protocol (25,26). However, the glycans on these glycoproteins are too
heterogeneous for a quantitative kinetic analysis, and furthermore, it is not possible to modulate
the glycan structure or location. Alternatively, chemically glycosylated proteins have also been
used for these studies because of the ability to control the size and degree of glycosylation (27).
However, the glycans used in these studies are not biologically relevant and the glycoproteins
produced are still heterogeneous at a molecular level.
In this study we investigated the effects of N-linked glycans on the rates of protein folding, using
protein samples that are homogeneously glycosylated with a biologically relevant chitobiose
(GlcNAc-3-1,4-GlcNAc) glycan (28). This disaccharide is common to all eukaryotic N-glycans
and has been previously found to have a significant effect on the conformation of polypeptides
(20). Our model protein is a small 87 amino acid, single domain, 4-helix bacterial protein called
immunity protein 7 (Im7), which is not natively glycosylated (29). Im7 is an ideal model protein
for the study of protein folding because it has a well-characterized folding mechanism and lacks
disulfide bonds, cis-proline amide bonds, and prosthetic groups that can complicate folding
kinetics (30). It also has a fortuitous W75 residue which is fluorescent when solvent exposed in
the unfolded state, and highly quenched in the native folded state when it is placed in close
proximity to H47. This allows the folding of Im7 to be monitored by stopped flow fluorescence
spectroscopy (30).
Using the semi-synthetic strategy as previously described in Chapter 2 (28), the asparagine-
linked chitobiose glycan was site-specifically introduced into seven locations of different
secondary structural motifs within the Im7 sequence (Figure 3-2). Glycosylation sites 20 and 73
are within the middle of a-helices, sites 13 and 73 are close to the termini of these a-helices, sites
5 and 60 are within flexible loop regions, and glycosylation site 27 is located in a loop region
following the end of helix I, a common motif found in N-linked glycoproteins. All the sites were
chosen to be solvent-exposed in order to minimize any obvious steric clashes that would prevent
the protein from folding to its native structure. This systematic placement of N-glycans at sites
of interest will allow us to thoroughly probe the effects of the glycans and determine whether
such effects are general or specific to the local secondary structure. Unlike studies involving
native glycoproteins, our semi-synthetic strategy allows us to look beyond native glycosylation
sites and focus on specific residues within locations of interest.
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Figure 3-2. Ribbon diagram of lm7 (pdb code 1AYI) with ligation (dark) and glycosylation
(blue) sites highlighted with spacefill side-chain representation. Amino acid sequence of Im7 is
shown below with the a-helices marked by boxes.
3-1. Measurements of Im7 folding kinetics
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Figure 3-3. Free energy diagram of Im7 three-state folding pathway with arbitrary free energy
scale. This linear progression from the unfolded, to the intermediate, and then the native state is
referred to as an on-pathway three-state model. The rate constants are experimentally
determined while the AG' values are calculated from the rate constants.
The folding of Im7 and its variants was studied using a stopped-flow fluorometer and procedures
adapted from previous studies on Im7 (31). To measure the rate of refolding, each protein
sample was dissolved in buffer at pH 7 containing 8 M urea denaturant and rapidly diluted with
buffers of varying urea concentration from 0.75 M to 8 M. To measure the rate of unfolding,
each sample was dissolved in buffer containing 0 M urea, and rapidly mixed with buffer
containing 3 to 8 M urea. The fluorescence of W75 was continuously monitored during the
mixing. Unlike many small single domain proteins, Im7 is known to fold by a three-state
mechanism through a highly populated on-pathway intermediate (Figure 3-3) (32), consisting of
three of the four native helices I, II, and IV and is stabilized by both native and non-native
interactions (33). The intermediate is formed within the instrument deadtime (5 js), making the
"U" to "I" transition too fast to be measured using our instrument. Therefore only the transition
from the intermediate to the native folded state can be directly measured (31). This means the
fluorescence signal can be fit to a single exponential function to determine the observed rate
constant (kobs) along with the initial and endpoint fluorescence.
A B
refolding unfldi nginitial fluorescence
, branch branch '-
Si -
__: LL e Sendpoint
- -a fluorescence
4 q a T 1 2 1 4 5 (l 7 6
[Urea] (M) .L. [Urea] (M)
Figure 3-4. Wildtype Im7: A) Chevron plot and B) initial and endpoint fluorescence plot. The
circles represent experimental data while the solid line represents the best fit to the on-pathway
three-state model.
Plotting the natural log of the kobs as a function of final urea concentration produces a Chevron
plot (32,34), which consists of a refolding branch at low concentrations of urea, an unfolding
branch at high concentrations of urea, and an inflection point in the middle corresponding to the
urea concentration at which the unfolded and the native structures are equal in stability (Figure
3-4). The Chevron plot for each variant can be globally fitted along with the normalized initial
and end point fluorescence data to an on-pathway three-state model (31). However, since the
intermediate is formed in the deadtime of the instrument, we fixed the ki of each variant to be
that of the wildtype Im7 previously measured using an ultra-fast mixing instrument. The other
three rate constants were obtained directly from the Chevron plot global fitting. The M-values
represent the compactness of the overall protein, and were also obtained directly from the
Chevron plot. From this mathematical analysis, we can obtain the kinetic and thermodynamic
parameters for each Im7 variant, producing a complete folding kinetic characterization for each
glycosylation site (Table 3-1).
3-2. Comparison of Im7 glyco-variants
Analysis of Im7 variants primarily involved comparing each glyco-variant to its corresponding
non-glyco pseudo-wildtype control (Figure 3-5). This allows one to determine the precise effect
of the chitobiose glycan oh the kinetic and thermodynamic properties of Im7, as the two variants
share the same peptide sequence and differ only by the presence of the glycan.
Table 3-1. The kinetic and thermodynamic parameters of each m7 variant obtained from the
global fitting of each Chevron plot and normalized initial and endpoint fluorescence data to an
on-pathway three-state model (31). Kui = k,,ikiu where ki is estimated to be a constant 1573 s-.
Mun is the global m-value, an indication that each Im7 variant has the same overall compactness.
AGui = -RTln(Kui) and AGun = -RTln(Kui kin/kni).
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Figure 3-5. Chevron plots of each Im7 glyco-variant (black) compared with the corresponding
non-glyco pseudo-wildtype control (blue). The circles represent experimental data while the
solid line represents the best fit to the on-pathway three-state model.
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Interestingly, the presence of the glycan can significantly affect both the rate of folding as well
as the rate of unfolding, and this effect is highly dependent on the local structure of the
glycosylation site (Figure 3-2). When the glycan was placed within a flexible loop region, such
as in variants N5 and N60, the presence of the glycan did not appear to affect the folding of Im7
(Figure 3-6). Similarly, when the glycan was placed near the N- or C-terminus of an a-helix,
such as in variants N13 and N78 respectively, the folding of Im7 was not perturbed. When the
glycan was placed in the middle of a helix, such as in variants N20 and N73, folding is adversely
affected signifying a less stable protein. However, the effect was not entirely the same for both
variants, as both the rate of folding and unfolding is changed in the N20 variant, but only the rate
of folding is affected in N73. In contrast, when the glycan was placed at a junction following the
end of helix I at position N27, the folding rates were increased while the unfolding rates
decreased, signifying an overall more stable protein.
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Figure 3-6. Comparison of the differences in the changes in free energy between the glyco-
variants and their corresponding non-glyco pseudo-wildtypes. Actual values come from Table
6-1. AAGoui = AGoui(glyco) - AGoui(non-glyco); AAGoun = AGun(glyco) - AGoun(non-glyco).
Although the absolute differences between the glycol- and non-glyco-variants are small, they are
significant relative to the overall stability of the protein. The total difference in free energy
between native and unfolded Im7 is only 24 kJ/mol. A 5 kJ/mol change in free energy as a result
of glycosylation represents more than 20% of the overall protein stability.
Despite the changes in folding kinetics observed, each glyco-variant of Im7 was still believed to
fold to the same native structure for the following reasons: Each glycosylation site was chosen
to be solvent exposed and contain no obvious interactions with its side chain to other residues.
Each Im7 variant was characterized by circular dichorism and shown to exhibit the same degree
of a-helical secondary structure as the wildtype (Chapter 2). Like wildtype Im7, each variant
was observed to fold through a hyper-fluorescent intermediate within the first 5 ps of refolding,
and its Chevron plots fit well to an on-pathway three-state model. Most importantly,
fluorescence of W75 was highly quenched in the folded state of each variant (Chapter 2), which
requires precise relative positioning of W75 with H47, consistent with a native fold. Therefore,
when examining AGoun, we make the assumption that the absolute free energy of the native state
remained the same among each variant, and any changes in free energy occurred as a result of
changes in the stability of the unfolded state.
3-3. Im7 N5 and N60 variants
Figure 3-7. Crystal structure highlighting glycosylation sites N5 and N60 (pdb 1AYI).
The glycosylation sites at residues 5 and 60 (as well as 27) were chosen because they are located
within loop regions of the protein (Figure 3-7). In a survey of 386 non-redundant glycosylation
sites from protein structures found in the RCSB Protein Data Bank, approximately 40% of N-
glycosylation occurred within loops, even though the overall incidence of loops within this data
set was only 25% (22). It is important to note that neither site represents the dihedral angles of a
p-turn, which has also been a commonly noted feature of eukaryotic N-link glycosylation. In
any case, the frequency of N-linked glycosylation within loop regions prompted a closer look at
the effect of placing an N-linked glycan within these structures.
Surprisingly, in both examples, the glycan exhibited little effect on the folding or unfolding
properties of the protein. This may be due to the fact that both regions of the protein are flexible
and solvent exposed, with no obvious nearby residues to interact with the glycan. Therefore,
while the protein collapses to its intermediate state and rearranges to the native fold, the presence
of the glycan can be accommodated without any noticeable changes in the folding process.
3-4. Im7 N20 and N73 variants
Figure 3-8. Crystal structure highlighting glycosylation sites K20N and K73N (pdb 1AYI).
The glycosylation sites at residues 20 and 73 are both located within the middle of a-helices (I
and IV respectively) (Figure 3-8). Importantly, N-linked glycosylation is not frequently
observed within a-helices. In the previous survey of known glycosylation sites, only 11% of N-
linked glycans were found within helices, compared with an overall incidence of helical structure
of 23% (22). In fact, a-helices represented the lowest incidence of N-linked glycosylation sites
amongst all types of secondary structures. It is therefore interesting to examine the effect of
glycosylation within these locations and understand the reason for this observation.
In both cases, the presence of the chitobiose disaccharide led to a destabilization of the overall
protein by approximately 5 kJ/mol. Specifically, for both variants, the rate of refolding was
significantly decreased relative to the corresponding pseudo-wildtypes. However, the rate of
unfolding for the N20 variant was increased while unfolding for N73 remains roughly
unchanged. The overall destabilization is likely to be caused by steric effects. Within the middle
of an a-helix, each amino acid side chains is in close proximity to the side chains of residues
three and four amino acids away in both directions, which are located on the adjacent turns of the
a-helix. The large size of the glycan attached to the asparagine side chain can cause it to clash
with side chains of amino acids one turn above and below. This steric interaction may stabilize
the unfolded state of Im7 relative to the native state since a random coil conformation is better
able to accommodate the steric bulk of the glycan as compared to an a-helix.
It is unclear exactly why the changes in unfolding rates for the two variants differ. However,
upon closer examination, it appeared that the two Chevron plots for the N20 and N73 glyco-
variants were very similar, and rather it was the unfolding rate for the N73 pseudo-wildtype that
was much higher than the other pseudo-wildtypes. This may be caused by additional
unfavorable interactions caused by the K73N mutation, such as non-native bonding with nearby
residues in the native or unfolded state, which is eliminated once N73 becomes glycosylated.
3-5. Im7 N13 and N78 variants
igure 3-9. Crystal structure highlighting glycosylation sites A13N and A78N (pdb 1AYI).
Both residues N13 and N78 are also found within a-helices (I and IV respectively) (Figure 3-9).
However, rather than at the center of a helix, N13 is located at the N-terminus and N78 is at the
C-terminus of the respective helices. In this case, the asparagine chitobiose side chain, rather
than being sandwiched between two amino acid side chains above and below, has significantly
more space to occupy and is therefore better able to avoid the unfavorable steric clashes
experienced by the N20 and N73 glyco-variants in the middle of the same helices. As a result,
glycosylation at both the N13 and N78 sites did not exhibit significant changes in their folding
kinetics.
3-6. Im7 N27 variant
Figure 3-10. Crystal structure highlighting glycosylation sites V27N and the type-1 f-burn at
that position (pdb 1AYI)
The N27 glyco-variant is unique within our set of Im7 variants because it was the only variant
that appears to significantly promote folding. The placement of the chitobiose glyan at N27
increased the rate of folding while decreasing the rate of unfolding, indicating an overall more
stable protein by approximately 4.5 kJ/mol in comparison to its relevant pseudo-wildtype control
(Figure 3-6). Residue 27 is located within the loop region between helices I and II, and is the
first residue within this loop following the end of helix I (Figure 3-10). Interestingly, it has been
observed in statistical analysis of N-linked glycoprotein that there is a highly increased
probability of glycosylation site occurring at or just after points in the peptide chain where there
is a change in secondary structure (22).
There are a number of effects that the glycan can impart at this critical position that would
promote folding. Firstly it may promote efficient folding by acting as a marker for the end of
helix I. It has been previously demonstrated within glycopeptides that N-linked glycans often
lead to a more compact f-turn structure through steric crowding (Figure 3-1) (20). In this case,
residue 27 does correspond to position "i + 1" of a type-1 3-turn. Therefore, it is possible that
placing the chitobiose glycan at position 27 simply help terminates helix I and promote the
formation of a 3-turn necessary within this loop region. Alternatively, it has also been shown
that N-glycans can promote folding by reducing the conformational freedom of the local peptide
backbone and thus reduce the loss of configurational entropy on folding (35). This is also a
plausible scenario since N27 is within a flexible loop which pays an entropic penalty when it
becomes structured in the native state. It is likely that both of these two factors promote the
folding of this Im7 variant.
Molecular dynamics simulations of short peptides corresponding to each glycosylation site are
currently being carried out. Because of their flexibility, the peptides should provide an
appropriate model for the unfolded state. By comparing the conformations of the peptides with
and without the glycan, we can more closely examine the effects of the glycan on the local
backbone structure.
Conclusion
To study the effects of N-linked glycosylation on protein folding, we have developed, for the
first time, a unique system involving a small, well characterized model protein, Im7, which is
homogeneously glycosylated with a biologically relevant chitobiose disaccharide glycan at seven
carefully selected sites of differing secondary structure. Like the wildtype Im7, each
glycoprotein variant appeared to fold through a well-populated folding intermediate and to the
same native folded structure as determined by fluorescence spectroscopy and circular dichroism.
Using stopped-flow fluorescence spectroscopy, the folding kinetics of each Im7 glyco-variant
was measured and compared with the corresponding non-glyco pseudo-wildtype control, which
contained the same peptide backbone sequence and differed only by the presence of the glycan.
The presence of the glycan can significantly affect both the rates of folding and unfolding, and
the overall effect appears to be highly specific to the local structure of the glycosylation site. In
summary, when the glycan was placed at a residue within a flexible loop or a non-sterically
hindered location of a helix, the glycan is accommodated with minimal effects on protein folding
rates. When the glycan was placed within the middle of a helix, where there can be possible
steric clashes with adjacent side chains on the same face of the helix, protein folding is impeded
most likely because the native structure is less able to accommodate the glycan in comparison to
the more open unfolded state. Interestingly, protein folding was promoted by the placement of a
glyan at a junction between a helix and the following turn, a common structural feature where N-
glycans are found. This effect may be caused by both the rigidifying of the peptide backbone
and the introduction of the turn to mark the end of the helix.
Experimental
Stopped flow kinetics measurements of Im7 variants.
Im7 variants of >95% purity were prepared as described in Chapter 5. Folding experiments were
adapted from previously published studies on Im7 (31). Fluorescence measurements were
carried out on an Applied-Photophysics SX1.8MV stopped-flow fluorimeter with the
temperature held constant at 10 'C. For unfolding experiments, Im7 variants were dissolved at a
concentration of approximately 0.35 mg/mL in buffer U [50 mM sodium phosphate, 400 mM
sodium sulfate, 1 mM EDTA (ethylenediaminetetraacetic acid), pH 7] and rapidly mixed by 1:10
dilution into solutions consisting of buffer U with urea concentrations of 3.0-8.0 M, at 0.25 M
increments. Refolding experiments were carried out in the same manner, except with Im7
variants dissolved in buffer U with 8 M urea, and mixed into solutions containing urea ranging
from 0.75-8.0 M.
At each urea concentration at least 7 kinetic traces were averaged and fit to a single exponential
function using the manufacturer's software in order to obtain the observed rate constant (kobs) as
well as the initial and final fluorescence signals. After subtracting the buffer blanks, the initial
and final fluorescence signals were normalized to the fluorescence signal of the 7.75 M urea
measurement. The kobs and normalized endpoint and initial fluorescence signals for each variant
were fit to the function of an on-pathway three-state model using Igor Pro 6.0 (Wavemetrics) as
previously described (31). The kui and mui were fixed to the values previously obtained for
wildtype Im7 from ultra-fast mixing continuous-flow measurements (k,,i = 1573 s- , mui = 1.23 kJ
mo1-1 M-1 ). Intermediate stability was determined by allowing kiu to vary (31).
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CHAPTER 4
CHEMO-ENZYMATIC SYNTHESIS OF
UNDECAPRENOL-LINKED SUBSTRATES
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Asparagine-linked glycosylation has long been considered a unique feature of the eukaryotic and
archaea kingdom. Recently, a gram-negative bacterium called Campylobacterjejuni became the
first bacterial organism discovered to also carry out this process (1-3). The enzymes involved in
this protein glycosylation pathway (Pgl) have since been identified and characterized (3-5). An
oligosaccharide is built up by a series of glycosyltransferases (PglC, A, J, H, I) on a
polyisoprenyl-carrier anchored to the periplasmic membrane (Figure 4-1). A flippase (PglK)
then flips the fully assembled glycan from the cytoplasmic to the periplasmic side of the
membrane where it is transferred by an oligosaccharyltransferase (PglB) from the polyisoprenol-
carrier to the asparagine side chain of the acceptor protein. Although the polyisoprenol-carrier
and the oligosaccharide are different to those in the eukaryotic pathways (Figure 4-2), the
process and machinery are highly analogous (6).
Table 4-1. Comparison of eukaryotic and prokaryotic N-linked glycosylation processes (6).
Characteristic Eukaryotic Bacterial
(Saccharomyces cerevisiae) (Campylobacterjejuni)
Location Lumen of the ER Bacterial periplasm
Timing Co-translational Post-translational
Dolichyl diphosphate-linked Undecaprenyl diphosphate-linked
tetradecasaccharide heptasaccharide
Glycosylation N-X-S/T where X f P D/E-X 1-N-X 2-S/T where X / P
sequence
Oligosaccharylligosaccharyl 8 subunit complex Single protein PglB
transferase
Glycan trimmingGlycan trimming In both the ER and Golgi No further processing
and elaboration
Oligosaccharide
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Figure 4-1. C. jejuni N-linked glycosylation pathway.
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heptasaccharide.
Although there has been much interest in the study of eukaryotic N-linked glycosylation, C.
jejuni provides many unique opportunities and advantages as a model for understanding this
complex process. Firstly, the C. jejuni pathway appears to be a more straightforward system
with fewer enzymes and substrates. There are only five glycosyltransferases, which have all
mI
been identified (3,4), whereas the eukaryotic system contains many more glycosyltransferases in
order to assemble its larger glycan (14 sugars vs. 7). There are only three types of sugars
involved and they are all activated as uridine diphosphate (UDP) derivatives, where as the
eukaryotic system also employs membrane-bound dolichyl phosphate-linked sugar donors.
Secondly, each enzyme within this pathway can be recombinantly overexpressed in E. coli (5),
which is a more convenient and robust protein production system in comparison to yeast, and
does not possess an interfering N-link glycosylation system of its own. Thirdly, the
oligosaccharyltransferase (OT) in C. jejuni appears to be fully functional as a single subunit,
which makes it a more promising target for mechanistic and crystallographic studies in
comparison to its 8-subunit eukaryotic counterpart. Finally, C. jejuni is a food-borne pathogen,
and it has been shown that the N-linked glycans play a critical role in host adherence, invasion,
and colonization (7). Therefore, understanding the C. jejuni N-linked glycosylation pathway
may facilitate the development of therapeutics towards the gastroenterological disorders caused
by this pathogenic bacterium.
In order to study the individual enzymes of C. jejuni Pgl pathway in vitro, access to the
substrates and substrate intermediates is required. Since C. jejuni is pathogenic and does not
produce a large amount of glycan substrates, purification from native sources is both unsafe and
impractical. To obtain large quantities of highly pure substrates, we employed a chemo-
enzymatic synthesis, combining the versatility of organic synthesis with the specificity and
selectivity of the enzymes from the C. jejuni Pgl pathway itself. This approach also offers the
advantage of incorporating tritium [ H]-radiolabels into the substrates, allowing for sensitive in
vitro assays in the low micromolar concentration range and the synthesis of unnatural substrate
analogues. Access to these radiolabeled substrates, intermediates, and analogues is essential in
allowing us to characterize and probe the enzymes of interest from this exciting new N-linked
glycosylation pathway. For example, Chapters 5 and 6 will demonstrate the usefulness of the
radiolabeled polyisoprenol-linked disaccharide produced in vitro for the evaluation of both the
peptide acceptor and polyisoprenol-carrier specificity in the oligosaccharyltransferase PglB.
4-1. Chemical synthesis of UDP-bacillosamine
The first sugar to be transferred to the undecaprenyl-carrier is the highly modified 2,4-
diacetamido-bacillosamine (2,4-diacetamido-2,4,6-trideoxy-3-D-glucopyranose), which will be
referred to as "bacillosamrine" in this dissertation. It is synthesized as the activated UDP sugar
nucleotide donor, and then transferred by the glycosylphosphotransferase, PglC, to the
undecapreyl phosphate-carrier (Figure 4-3) (8). This unusual sugar also appears to be an
important feature of bacterial O-linked glycosylation, as its derivatives have been discovered in
numerous other bacteria (9), including the O-linked pillin glycosylation system of Neisseria
gonorrhoeae (10). In C. jejuni, bacillosamine is especially important since this sugar is present
in all N-linked glycoproteins as well as in every undecaprenol-linked intermediate.
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Figure 4-3. Biosynthesis of undecaprenyl diphosphate-bacillosamine using PglC.
Because UDP-bacillosamine is not commercially available, a chemical synthesis was designed
and carried out by Dr. Eranthie Werapana in our laboratory. This multi-step synthesis allowed
for the production of highly pure UDP-bacillosamine in milligram quantities starting from
commercially available galactosamine (Figure 4-4) (8,11). However, the yield of this synthesis
was modest, not only because the protocol was lengthy but also because the synthesis was
entirely linear. From 10 g of galactosamine, approximately 15 mg of UDP-bacillosamine can be
produced following the original protocol, corresponding to an overall yield of -0.5%.
Furthermore, chemical intermediates of sufficient purity for NMR characterization were difficult
to obtain. To improve upon the yield and purification protocol of the original synthesis, a
number of small adjustments were made to optimize each step, including two notable changes.
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(a) Ac 2 0, pyridine; (b) FeC13, CH 2C12; (c) BnOH, Tos-OH, toluene, MeNO 2, 1100°C; (d) NaOMe, MeOH; (e) BzCI, pyridine, -40 to 00C;
(f) i) Tf20, CH 2C12/pyridine, 00C to rt; ii) NaN 3 , DMF; (g) NaOMe, MeOH; (h) TsCI, pyridine, 00C to rt; (i) Nal, MeCN, 800C;
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Figure 4-4. Original chemical synthesis of UDP-bacillosamine starting from commercially
available galactosamine (8,11).
To achieve benzyl protection of the anomeric hydroxyl, the original protocol employed a two-
step approach, involving the formation of an oxazoline followed by subsequent ring opening
with benzyl alcohol to produce the product as a "pale brown solid" with an overall yield of 67%.
Both the yield and purify of the product was improved though the use of a one-step protocol
using BF 3 etherate as a Lewis acid, producing the desired product as a white crystals in 87%
yield (Figure 4-5).
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Figure 4-5. Improved approach to anomeric benzyl protection using BF3 etherate.
For the purification of many chemical intermediates, the original protocol employed a
chloroform/methanol solvent system for silica flash chromatography. However, due to the polar
N-acetyl groups present in each intermediate, an ethylacetate/hexane/methanol system was found
to provide superior separation amongst the compounds with and without the N-acetyl groups.
The use of this solvent system led to greater purity of each chemical intermediate for NMR
characterization.
Optimization of the original chemical synthesis led to an overall 12-fold improvement in yield
and allowed publication-quality NMR spectra (11) to be obtained for many of the synthetic
intermediates that were previously difficult to purify. Access to large amounts of UDP-
bacillosamine was essential for the subsequent synthesis of undecaprenol-linked substrates that
are necessary in the studies of enzymes in the Pgl pathway. Furthermore, this UDP-
bacillosamine was also applied to the study of the related N. gonorrhoeae glycosylation pathway
in our lab, when it was discovered that this pathway also uses UDP-bacillosamine as a key
substrate.
4-2. Enzymatic synthesis of undecaprenyl diphosphate-linked compounds
Conveniently, each of the undecaprenol-linked intermediate can be synthesized in vitro using the
glycosyltransferases from the Pgl pathway. PglC can be used to transfer bacillosamine
phosphate from UDP-bacillosamine to undecaprenyl phosphate, creating the first undecaprenol-
linked intermediate: undecaprenyl diphosphate-bacillosamine (8). PglA, J, and H can then
sequentially add five N-acetylgalacosamine (GalNAcs) to this substrate from UDP-GalNAc,
each with a-1,4 linkages (Figure 4-1) (12). Finally, PglI adds the final glucose to the third
GalNAc in a -1,3 linkage (12). Each enzyme was either recombinantly overexpressed in E. coli
with a C-terminal His6-tag and purified to homogeneity by Ni-NTA affinity chromatography, or
they were used as a semi-pure membrane envelope fraction for ease of handling. These
glycosyltransferases require no cofactor except for Mg2 + metal, and can function together
efficiently in a one-pot 5-enzyme in vitro reaction to produce only the expected product (Figure
4-6) (12). The synthesis of any intermediates within the pathway can be carried out by simply
excluding the appropriate glycosyltransferase and UDP-sugar donor.
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Figure 4-6. One pot enzymatic synthesis of undecaprenyl diphosphate-heptasaccharide, the
native glycan donor in the C. jejuni N-linked glycosylation pathway.
The hydrophobic undecaprenyl-linked compounds can be isolated from the hydrophilic UDP-
sugar starting materials by extraction using organic solvents (Figure 4-7). Upon completion of
the reaction, usually lasting 2-3 hours, the reaction mixture is quenched with a
chloroform/methanol solution, resulting in a phase separation between the aqueous and organic
fractions. The water-soluble UDP-sugars remain in the aqueous fraction, while undecaprenol-
linked compounds are extracted into to the organic fraction due to their extremely hydrophobic
aliphatic component. Multiple extractions allow for nearly quantitative separation of those two
reaction components. To purify the individual undecaprenyl-linked glycan intermediates, a
semi-preparative normal-phase HPLC was used, which offers quick and effective baseline
separation of intermediates that differ even by a single sugar.
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Figure 4-7. Separation of undecaprenol-linked products from excess starting material using
organic solvents extractions, following a glycosyltransferase reaction.
An additional aspect of the enzymatic synthesis of undecaprenol-linked substrates was the
incorporation of tritium radiolabels, which allowed for the detection and sensitive quantification
of these substrates in enzymatic assays. Tritium radiolabels were typically introduced through
the use of commercially available UDP-[C6-3H]GalNAc, which can be spiked into the reaction
mixture to create a known concentration of UDP-GalNAc of the desired specific activity, and
any glycosyltransferase from the pathway that uses UDP-GalNAc. For glycosyltransferase
assays, reactions were monitored based on the amount of water soluble UDP-[C6-3H]GalNAc
transferred to the organic soluble undecaprenyl diphosphate-carrier. For
oligosaccharyltransferase assays, reactions were monitored based on the amount of organic
soluble undecaprenyl diphosphate-linked [3H]glycan transferred to the water-soluble peptide
acceptor. This ability to incorporate radiolabels is a major advantage, as non-radiolabeled
substrates isolated from biological sources do not offer such a useful handle for quantification.
Progress that was later made in our laboratory allowed for a more convenient and quantitative
biosynthesis of UDP-bacillosamine from UDP-GlcNAc using the three biosynthetic enzymes
from the Pgl pathway: PglF, E, and D (Figure 4-8). Interestingly, it was found that these three
enzymes can also be incorporated with the five glycosyltransferases to synthesize the full-length
undecaprenyl diphosphate-heptasaccharide in a one-pot reaction starting with undecaprenyl
phosphate and the commercially available UDP-sugar nucleotides (13). The specificity of PglC
only allows bacillosamine to be transferred to the undecaprenol-carrier and does not appear to
recognize the biosynthetic intermediates created by PglF or E. This new one-pot 8-enzyme
synthesis offers the most convenient and efficient synthesis of undecaprenol-linked compounds,
and represents an improvement over the previous chemical synthesis.
PgIF PglE PgID
HO NH 2  O AcHN 0 D
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Figure 4-8. Biosynthesis of UDP-bacillosamine using Pgl F, E and D from the Pgl pathway.
4-3. Testing the binding of undecaprenyl diphosphate-linked substrates to lectins
The undecaprenol-linked substrates can find useful applications in any assay or study that
requires a sensitive method for quantifying the attached glycan. Lectin binding was one such
case where these compounds were used (14).
For example, a significant amount of in vivo research on the Pgl pathway was not carried out in
the native C. jejuni host organism, but rather in a strain of E. coli transformed with the Pgl locus
(5). This is mainly because C. jejuni is a pathogenic bacterium, while E. coli has already been
established as a versatile organism for protein production and bioengineering. Although the
glycosylation machinery appears to be functional within E. coli, it is important to determine
whether the biosynthetic production of undecaprenol-linked substrates is the same as in the
native organism. In order to make this comparison, our collaborators from the National Research
Council of Canada designed a method of extracting and purifying the undecaprenol-linked
substrates from cells and identifying the isolated samples by capillary electrophoresis mass
spectrometry. Their extraction protocol is similar to our own, using chloroform/methanol
solvents, but it also includes an additional enrichment step involving soybean agglutinin (SBA)
lectins for affinity capture of GalNAc containing compounds (14). However there was no
convenient method for them to evaluate the binding efficiency of the SBA lectin to determine
whether it was reproducible and quantitative.
The tritium-labeled substrates produced from our synthesis were well suited to be used as
standards for evaluating the binding of undecaprenyl-linked substrates to lectin. The radiolabel
can easily allow detection of substrates down to the nanomolar concentration range. To evaluate
effectiveness of lectin binding, each of the GalNAc containing undecaprenyl-linked intermediate
from the Pgl pathway was synthesized, purified, and then incubated with SBA resin. The
supernatant was removed and the resin washed with buffer to remove unbound substrate. Finally
the substrates were eluted from the SBA resin using a concentrated solution of GalNAc. The
radioactivity from the unbound supernatant, the washes, the elution, and the resin can then be
quantified by scintillation counting (14).
The first experiment involved a 1:1:1:1 mixture of undecaprenol-linked disaccharide,
trisaccharide, hexasaccharide, and the full length native heptasaccharides. It was found that
approximately 70% of the total substrate bound to the resin, while a significant amount remained
in solution following the incubation (Figure 4-9). This incomplete binding does not appear to be
due to insufficient resin, as doubling the amount of resin did not significantly improve binding.
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Figure 4-9. Evaluation of SBA-lectin binding of a 1:1:1:1 mixture of undecaprenyl diphosphate-
linked disaccharide, trisaccharide, hexasaccharide, and the full length native heptasaccharides.
A second set of experiments were carried out to evaluate the binding of each substrate
individually (Figure 4-10). A correlation was discovered between the number of GalNAc
residues present in the substrate and the affinity of that substrate for the lectin resin. For the
native heptasaccharide, approximately 85% of the substrate remained bound to the resin after
washing. In contrast, for the disaccharide, containing a single GalNAc residue, only 40% of the
substrate remained bound to the resin, while the rest either was released during the wash or never
bound at all.
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Figure 4-10. Evaluation of SBA-lectin binding of undecaprenyl diphosphate-linked
disaccharide, trisaccharide, hexasaccharide, and heptasaccharides substrates individually.
Despite the incomplete binding, each of the undecaprenyl-linked substrates was confirmed to
bind to the SBA resin. The results from these binding assays were remarkably reproducible,
differing between experimental repeats by less than 5%. Therefore, when comparing the
differences in substrate synthesis between C. jejuni and E. coli, affinity capture with SBA can be
a viable method of isolation of GalNAc containing substrates. Since lectin binding is typically
known to be weak and cooperative, it was not surprising to observe that better binding was
achieved by larger glycans that contained more GalNAc residues.
Conclusion.
In order to probe the enzymes involved in the newly discovered N-linked glycosylation pathway
in C. jejuni, we developed an efficient chemoenzymatic in vitro synthesis for the unusual UDP-
bacillosamine sugar as well as for each of the undecaprenol-linked substrate intermediates found
in the pathway. Our synthetic strategy allowed us to access milligram-quantities of the desired
substrates with high purity. Importantly, it allowed us to conveniently incorporate radiolabels
into each compound as handles for accurate quantification in any in vitro assay, which is not
possible with natively isolated substrates. Furthermore, it offered us the versatility of making
unnatural analogues not available from native sources.
To demonstrate one practical use for these radiolabeled substrates, we synthesized four
undecaprenol-linked glycans of varying size and evaluated their binding efficiency to SBA-
lectin. Although each substrate was recognized by the lectin, there was a direct correlation
between the number of GalNAc residues present in the substrate and the strength of the binding.
Such an analysis could not have been made without access to pure, homogenous, and
radiolabeled substrates. The next two chapters will describe further studies where these synthetic
substrates were used to probe and characterize the enzymes of the Pgl pathway.
Experimental
Anomeric benzvl protection of peracetlated galacosamine.
BnOH
OAc BF 3-Et2O OAc
AAcO-O-
AcOOAc MeCN OAcO. Bn
NHAc 80 C NHAc
Peracetylated galactosamine (17.25 g, 44 mmol) was dissolved in acetonitrile (75 mL, HPLC
grade >99.9%). BF 3-diethyl etherate (300 gL, 2.4 mmol) and benzyl alcohol (10 mL, 100 mmol)
was added to the mixture and heated to reflux at 80 oC for 3 hours. The acetonitrile solvent was
removed under vacuum, and the precipitate was dissolved in 9:1 ethyl acetate / methanol for
recrystallization, from which 14.4 g of highly pure benzyl glycoside product was isolated. The
mother liquid was applied to flash chromatography using a 50:45:5 ethyl acetate / hexane /
methanol solvent system, from which 2.8 g of pure benzyl glycoside product was isolated.
Combined with the recrystallized product, an overall yield of 87% was obtained.
Synthesis of undecaprenyl diphosphate-heptasaccharide using UDP-bacillosamine.
HOH OH O OHOH
HO OH 0
.OH0 0
detergent (7 L of 14.3% stock) with rigorous vortexing and sonication (water bath). To this
HO O
Dried undecaprenyl phosphate (5 nmol) was resuspended using DMSO (3 gL) and Triton X-100
detergent (7 giL of 14.3% stock) with rigorous vortexing and sonication (water bath). To this
mixture was added UDP-bacillosamine (10 nmol), UDP-GalNAc (100 nmol), UDP-glucose (10
nmol), and brought to a total volume of 55 gL with final buffer concentrations of 50 mM tris-
acetate, 10 mM MgCl 2, pH 8.5. Next, purified glycosyltransferases PglC, PglA, PglJ, and PglH
were added (5 gL each, -0.5 mg/mL), followed by PglI cell envelope fraction (25 pL). Enzyme
preparation carried out as described in the literature (8,12). The reaction was thoroughly mixed
and allowed to proceed for 120 min at room temperature. To isolate the undecaprenyl-linked
products, the reaction mixture was quenched by the addition of PSUP (160 gL) and a 2:1 mixture
of chloroform / methanol (800 ptL). The tube was centrifuged briefly, and the organic (bottom)
layer containing the desired products were removed and dried under reduced pressure.
Synthesis of undecaprenvl diphosphate-heptasaccharide using UDP-GlcNAc and bacillosamine
biosynthesis enzymes.
HOOH 0
OH 0  AcHNO OH0
H H H HAcHNO 
N
AcHN0
0- 0
- -o--Oi-
3
Dried undecaprenyl phosphate (5 nmol) was resuspended using DMSO (3 gL) and Triton X-100
detergent (7 gL of 14.3% stock) with rigorous vortexing and sonication (water bath). To this
mixture was added UDP-GlcNAc (100 nmol), UDP-GalNAc (100 nmol), UDP-glucose (20
nmol), NAD' (50 nmol), L-glutamate (2000 nmol), PLP (25 nmol), AcCoA (100 nmol) and
brought to a total volume of 40 gL with final buffer concentrations of 50 mM tris-acetate, 10
mM MgCl2, pH 8.5. Next, purified enzymes PglD, PglC, PglA, PglJ, and PglH were added (4
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mM MgCl 2, pH 8.5. Next, purified enzymes PglD, PglC, PglA, PglJ, and PglH were added (4
gL each, -0.5 mg/mL), followed by PglE (10 gL, -0.5 mg/mL), PglF (20 gL, 0.15 mg/mL), and
PglI cell envelope fraction (10 gL). Enzyme preparation was carried out as described in the
literature (8,12,13). The reaction was thoroughly mixed and allowed to proceed for 7 hours at
room temperature. To isolate the undecaprenyl-linked products, the reaction mixture was
quenched by the addition of PSUP (160 gL) and a 2:1 mixture of chloroform / methanol (800
gL). The tube was centrifuged briefly, and the organic (bottom) layer containing the desired
products were removed and dried under reduced pressure.
Synthesis of radiolabeled undecaprenyl-linked substrates.
To synthesize radiolabeled substrates, one of commercially available tritiated substrates (UDP-
[C6-3 H]GalNAc, UDP-[C6-3H]GlcNAc, UDP-[C6- 3H]Glucose, or [3H]AcCoA) was substituted
for the corresponding non-radiolableld component of the reaction. Typically the radiolabeled
substrate was diluted with the corresponding non-radiolabeled to achieve the desired specific
activity. Unless otherwise stated, radiolabel used in this thesis was incorporated as UDP-[C6-
3H]GalNAc.
Synthesis of truncated undecaprenvl-linked substrates.
To synthesize truncated undecaprenyl-linked substates, such as the undecaprenyl diphosphate-
disaccharide, trisaccharide, and hexasaccharide, the appropriate glycosyltransferase and UDP-
glucose was neglected from the reaction, as well as a reduction in UDP-GalNAc concentration
depending on stoichiometry.
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Purification of undecaprenyl-linked substrates.
Undecaprenyl-linked substrates isolated from the reaction mixture by organic extraction was
dried under reduced pressure and resuspended in 2:1 mixture of chloroform / mechanol. This
mixture was separated on a normal-phase Varian Microsorb HPLC column using the following
gradients at 1 mL/min flow rate: 0-3 min at 0% B; 3-5 min at 0-20% B; 5-35 min at 20-30% B;
35-60 min at 30-45% B; 65-70 min at 100% B; where A = 4:1 chloroform / methanol, and B =
10:10:3 chloroform / methanol / 2 M ammonium acetate.
Undecaprenvl-linked substrate lectin binding assays.
Dried undecaprenyl diphosphate-oligosaccharide[ 3 H-GalNAc] (0.13 nmol) was resuspended
using a 9:1 mixture of ethanol / methanol (40 gL) with rigorous vortexing and sonication. It was
diluted with 360 RpL of buffer A [10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic sodium salt), 3.4 mM EDTA (ethylenediaminetetracetic acid), 150 mM NaCl, pH
7.4], followed by the addition of SBA resin (20 pL) pre-equilibrated with buffer A. This mixture
was left to rotate at 4 'C for 2 hours. Supernatant was then removed and the resin washed with
buffer A (400 L). The resin was then incubated for 3 x 15 min with 400 / 200 / 200 gL of 200
mM galactose solution at each incubation. The unsuspended residue, the supernatant and wash,
the elution, and the resin were individually subjected to scintillation counting. Each experiment
was carried out in duplicate.
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CHAPTER 5
OLIGOSACCHARYLTRANSFERASE PGLB ACCEPTOR SPECIFICITY
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In the eukaryotic kingdom, N-linked glycosylation takes place on the asparagine side chain of
the acceptor protein within the consensus sequence Asn-X-Ser/Thr, where X can be any amino
acid except for proline (1-3). Although this sequence is necessary for glycosylation to occur, it is
not sufficient, as many potential glycosylation sites have been known to be either unglycosylated
or inefficiently processed (4). Factors that influence glycosylation site occupancy and efficiency
include the choice of serine or threonine hydroxy-amino acid, the local sequence and secondary
structure, the amino acid in the X-position, and the proximity of the glycosylation site to the C-
terminus of the protein (5).
Recently, Campylobacter jejuni became the first and, thus far, only bacterium discovered to
contain a general N-linked protein glycosylation system (6,7). Although the specific substrates
are different, this protein glycosylation (Pgl) pathway appears to be very analogous to the
eukaryotic pathway. Central to this pathway is the oligosaccharyltransferase (OT) PglB, an 82
kDa integral membrane protein with significant sequence homology to the Stt3p subunit of the
eukaryotic OT, which is believed to contain the catalytic domain (8,9). PglB catalyzes the
transfer of the preassembled heptasaccharide from the undecaprenyl diphosphate-carrier to the
asparagine side chain of the polypeptide acceptor. We have previously demonstrated the OT
activity of PglB in vitro using a synthetic radiolabeled disaccharide glycosyl donor and a short
peptide acceptor (10). However, little is known about the acceptor sequence preferences for this
prokaryotic OT, which is crucial for understanding the factors that govern glycan site occupancy
and how it differs in comparison to the better known eukaryotic system. Furthermore,
information regarding the binding preferences of PglB can aid in the design of tight binding
inhibitor for mechanistic studies.
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Native PglB Reaction
in vivo
PglB
protein undecaprenol-PP
Simplified PglB Reaction
in vitro
PglB
protein undecaprenol-PP
Figure 5-1. Comparison of native PglB reaction in vivo and the tritium labeled simplified
reaction for assays in vitro. The rectangles represent the full length protein.
5-1. Design and synthesis of PglB peptide acceptors
In order to assay PglB in vitro, both the glycan and the protein acceptor were slightly modified.
Instead of the full-size native heptasaccharide, we used a truncated tritium-labeled disaccharide
(undecaprenyl diphosphate-bacillosamine-a-1,3-GalNAc) (Figure 5-1). The radiolabel provides
the signal sensitivity needed to carry out the assay in the low micromolar concentration range,
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which would not be possible with native substrates. The smaller disaccharide is easier to
synthesize (11), has better solubility properties, and has already been demonstrated to be well
accepted by PglB (10). Although N-linked glycans are only found attached to proteins in vivo,
both the eukaryotic OT and PglB have been demonstrated to glycosylate small flexible peptides
in vitro. Peptides make ideal acceptors for in vitro assays because they can be easily synthesized
by solid phase, they can be made to include unnatural amino acids to probe the binding of the
enzyme, and they contain virtually any sequence without concern for disrupting the protein fold.
In this study we designed and synthesized a library of peptide acceptor substrates for PglB.
Using a sensitive radioactivity-based in vitro assay, we proceeded to define the minimal
glycosylation consensus sequence recognized by PglB and the amino acid preference at each
residue location. Our peptide template was based on a known glycosylation site 88DFNVS 9 2
from the C. jejuni glycoprotein PEB3 (12,13). A para-nitrophenylalanine (pNF) (Figure 5-1)
was appended to the C-terminus of each peptide to facilitate accurate peptide concentration
determination by UV/Vis spectroscopy. All peptides were capped at both termini to simulate an
interior peptide sequence, because this has been previously shown to improve binding for the
eukaryotic OT (2). Each peptide only differed by a single amino acid, so that the contribution of
each residue within the glycosylation sequence could be systematically evaluated (Figure 5-2).
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-G-K-D-F-N-V-S-K-I -
-D-F-N-V-S-
-D-F-N-V-T-
-D-F-N-V-C-
-D- F -N-V-A-
-D-F-N-V-Hse-
-D- F-N-V-Dap-
-E-F-N-V-S-
-A- F -V- -
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-D-W-N-V-S-
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-D- S-N-V- S-
-D-N-N-V-S-
-D-Q-N-V-S-
-D-D-N-V- S -
-D-E-N-V-S-
-D-R-N-V-S-
-D-K-N-V-S-
-D-G-N-V-S -
-D-P-N-V- S-
-D-F-N-V- S -
-D-F-N-Y-S-
-D-F-N-W-S-
-D-F-N-H-S-
-D-F-N-A- S-
-D-F-N-F-S-
-D-F-N-S-S-
-D-F-N-N-S-
-D-F-N-Q-S-
-D-F-N-D-S-
-D-F-N-E-S-
-D-F-N-R-S-
-D-F-N-K-S-
-D-F-N-G-S-
-D-F-N-P-S-
Figure 5-2. Sequence of peptides synthesized for evaluation of PglB. Each peptide contained a
C-terminus para-nitrophenylalanine for concentration determination. Hse = homoserine, side
chain extended from serine by one methylene group. Dap = 2,3-diaminopropionic acid, side
chain truncated from lysine by two methylene groups.
5-2. Evaluation of PglB glycosylation sequence preferences
The consensus N-linked glycosylation sequence in C. jejuni shared both interesting similarities
and differences with the eukaryotic counterpart. One major difference in C. jejuni glycosylation
was the additional requirement of an acidic residue (aspartate or glutamate) at the -2 position.
Although under high substrate concentrations we observed glycosylation of the Asn-Leu-Thr
peptide in vitro (10), the acidic residue appeared to be necessary for efficient glycosylation to
take place (Figure 5-3). Although aspartate and glutamate are equally common at the -2 position
of N-linked glycosylation site from C. jejuni glycoproteins, we found that PglB exhibited a
distinct preference for aspartate at that position. Between the two model peptides Ac-EVNAT-
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(pNF)-NH2 and Ac-DVNAT-(pNF)-NH 2, having glutamate as the acidic residue at position -2
increased the K,,(app) by six-fold, while decreasing the Vmax(app) by five-fold (Table 5-1).
Eukaryotic - Asn - X - Ser/Thr -
C. jejuni - Asp/Glu - X, - Asn - X2 - Ser/Thr -
-2 -1 0 +1 +2
where X Pro
Figure 5-3. Minimum glycosylation consensus sequence of the eukaryotic and C. jejuni OT.
Peptides containing threonine, as the hydroxyamino acid at position +2, exhibited a three-fold
lower Km(app) in comparison to serine (Table 5-1). This preference for threonine is shared by the
eukaryotic OT, wherein substitution of serine for threonine can dramatically improve the
glycosylation efficiency of a poorly-glycosylated site in vivo (14,15). The effects of the
substitutions appeared to be additive. When both unfavorable amino acids were present within
the same peptide Ac-EFNVS-(pNF)-NH 2, glycosylation was negligible under the experimental
conditions employed. This was initially surprising since the C. jejuni glycoprotein HisJ is known
to be glycosylated at the site 27ESNAS31, although somewhat less efficiently than other C. jejuni
glycoproteins (12).
Peptide conformation appeared to be an important factor for substrate recognition, as was shown
for the eukaryotic OT (16). The unnatural peptides containing structural analogs cysteine,
homoserine, or diaminopropionic acid at the +2 position were not found to be glycosylated by
PglB to a noticeable degree under the assay conditions employed. Furthermore, these three
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peptides did not exert any inhibitory effect on the glycosylation of other acceptor peptides,
suggesting that they are not well recognized by PglB. Our interpretation of the finding is that the
poor glycosylation activity is due to the fact that these peptides are less capable of forming the
Asx-turn, a motif suggested to be recognized by the eukaryotic OT (17-19).
Table 5-1. Kinetic parameters of PglB peptide substrates. Unnatural amino acids: pNF = para-
nitrophenylalanine, Hse = homoserine, Dap = 2,3-diaminopropionic acid.
PVmax(pp) Km(app) Vmax(app/Km(app)
(nM/min) (pM) (min -1 x 103)
Ac-DFNVA-(pNF)-NH 2  no activity
Ac-DFNVT-(pNF)-NH 2  34.6 ± 0.5 1.22 ± 0.07 28.4 ± 1.80
Ac-DFNVS-(pNF)-NH 2  34.6 ± 1.2 3.83 ± 0.55 9.03 ± 1.45
Ac-AFNVT-(pNF)-NH2 no activity
Ac-EFNVT-(pNF)-NH 2  6.9 _ 0.3 23.3 ± 2.98 0.30 ± 0.04
Ac-EFNVS-(pNF)-NH 2  no activity
Ac-GKDFNVSKI-(pNF)-NH 2  11.3 _ 0.3 1.17 ± 0.14 9.67 ± 1.26
Ac-DFNVC-(pNF)-NH 2  no activity
Ac-DFNV-(Hse)-(pNF)-NH 2  no activity
Ac-DFNV-(Dap)-(pNF)-NH 2 no activity
In the same manner, we evaluated the preferences of PglB for the amino acids in the two X-
positions (Figure 5-4). For the XI-position, PglB revealed a clear preference for the amido
functionalities of asparagine and glutamine, as well as for large hydrophobic groups, whereas
charged amino acids were clearly disfavored at that position. For the X2-position, PglB exhibited
trends similar to the eukaryotic OT (20), in which the positively charged groups of lysine and
arginine, along with alanine and serine were favored, while large hydrophobic groups were
disfavored. The differences within this set of peptides mainly comes from the differences in
Kin(app), while the relative Vmax(app) Values are similar and do not follow the same trend. Like the
111
eukaryotic OT, proline was not accepted at either of the two X-positions. It is interesting that
PglB has such contrasting preference for the two residues directly adjacent to the glycosylation
site. Within the peptide library presented, the DQNAT sequon was found to be the optimal
peptidyl substrate for PglB.
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Figure 5-4. Comparison of PglB initial rates with peptides substrates varying at the Xi and X2
positions. Peptides were assayed at 10 pM concentration, close to the average peptide K,n(app).
The extended PEB3 peptide Ac-GKDFNVSKI-(pNF)-NH 2 was found to have a lower Km(app)
than its corresponding hexapeptide counterpart, indicating the presence of additional binding
determinants in the substrate beyond the minimum consensus sequence (5). However, direct
comparisons are complicated by the pNF residue being in a different a position from the rest of
the peptides within the library.
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5-3. Preparation of full-length folded protein as acceptors for PglB
In eukaryotic systems, N-linked glycosylation takes place as a co-translational process, in which
the glycan is transferred to the nascent protein acceptor while the protein is being synthesized by
the ribosome and threaded through the ER membrane by the translocation machinery (21). The
eukaryotic OT is not capable of glycosylating folded proteins, and has a clearly demonstrated
requirement for unstructured and flexible acceptors (22). In C. jejuni, protein synthesis takes
place in the cytoplasm, while N-linked glycosylation takes place in the periplasm (21). It is
unclear whether the glycan is transferred in a homologous manner to the eukaryotic system as
the protein is translocated into the periplasm, or whether it occurs on fully folded protein
acceptors already present in the periplasm.
To determine whether PglB has the ability to glycosylate a full-length folded protein, we
engineered a Asp/Glu-X1-Asn-X 2-Ser/Thr glycosylation consensus sequence into a well-defined
loop region within Im7 (23-25), a small bacterial non-C. jejuni protein which is not glycosylated
(Figure 5-5). Loops are the most common type of secondary structure where N-linked
glycosylation is found, and are expected to be more tolerant of the mutations needed to create a
PglB glycosylation sequence. Point mutations N26D and A28N resulted in the formation of a
glycosylation consensus sequence 26DVNAT 30 within the loop region between the first and
second helices of Im7. The overall structure of the Im7 mutant was compared with the wild-type
using circular dichroisn spectroscopy (CD) in order to verify that introduction of the
glycosylation sequence did not significantly change the overall fold of the protein (Figure 5-6).
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helix-2
Figure 5-5. Native Im7 structure,
helix-II (26), pdb code 1CEI.
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Figure 5-6. Comparison of Im7 mutants to wildtype Im7 secondary structures by circular
dichroism spectroscopy.
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5-4. PglB glycosylation of full length folded proteins
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Figure 5-7. Reverse-phase HPLC traces of lm7 mutant 26DVNAT 30 before and after
glycosylation by PglB. Elution of protein was monitored by absorbance at 228 nm, and collected
in 1 mL fractions for scintillation counting. The extent of glycosylation was quantified by the
amount of radiolabeled disaccharide co-eluting with the protein acceptor.
The Im 7 DVNAT mutant was incubated with PglB and the radiolabeled glycosyl donor for 3 hours.
When the sample was subjected to a reverse-phase HPLC analysis, a significant amount of
radioactivity was found to co-elute with a 228 nm absorption peak corresponding to the Im7
protein (Figure 5-7). No appreciable radioactivity was found to be associated with the wild-type
Im7NVAAT and the non-glycosylatable Im 7DVAAT mutant, missing the asparagine glycosylation
site. As a negative control, radioactivity was not found to be associated with the Im7 mutant
when PglB was not present, or when the eukaryotic OT was used with its native glycan donor
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substrate (data not shown). Mass spectral analysis confirmed that the disaccharide was indeed
covalently linked to the Im7DVNAT mutant (Figure 5-8). It appears that a major difference
between prokaryotic and eukaryotic N-linked glycosylation is that PglB possesses the ability to
glycosylate already folded proteins independent of the translocation machinery, whereas the
eukaryotic OT requires the acceptor to be flexible and unconstrained by tertiary structure.
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Figure 5-8. Electrospray ionization mass spectral analysis of glycosylated Im7 mutant26DVNAT30 following PglB glycosylation reaction. Masses in grey correspond to remaining
unglycosylated Im7, while masses in black correspond to Im7 plus the disaccharide.
To determine whether the preferences and trends observed in the peptide acceptor study are
relevant in the context of a fully folding protein, a small set of Im7 mutants varying in the
glycosylation sequence was created to compare their ability as glycosylation acceptors. Like the
previous mutant, each new Im7 was checked by CD to ensure that the mutations did not affect
the structure of the protein. When assayed with PglB, the relative extents of glycosylation were
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consistent with the glycosylation efficiencies of the corresponding peptides. However, the
differences amongst the full-length proteins were less dramatic (Table 5-2). Our interpretation
of this finding is that, similar to the eukaryotic OT, the acceptor binding of PglB is influenced by
residues beyond the five amino acid consensus sequence, and that local structural conformation
near the glycosylation site diminishes the effects of the glycosylation sequence. Nevertheless,
Im 7 DQNAT mutant with the optimal glycosylation sequence as determined by the peptide study
was the most efficiently glycosylated by PglB, indicating that the overall residue preferences of
PglB are the same regardless of whether the substrate is a structured protein or a flexible peptide.
Table 5-2. Kinetic parameters of PglB peptide substrates in comparison to the glycosylation of
corresponding Im7 mutants. The extent of glycosylation corresponds to the percentage of
(limiting) radiolabeled glycosyl donor consumed in the 3-hour reaction.
Peptide Vmax(app) Km(app) Vmax(app/Km(app) m Mutant Extent of
S(nM/min) (M) (min- x 103)  Glycosylation
Ac-NVAAT-(pNF)-NH 2  no activity Native 0 ± 0.0
Ac-DVAAT-(pNF)-NH 2  no activity 26DVNAT30  0 + 0.0
Ac-EVNAT-(pNF)-NH 2  50.6 ± 1.6 22.5 ± 2.56 2.3 ± 0.29 26EVNAT 30  22 ± 6.3
Ac-DVNAS-(pNF)-NH 2  31.0 ± 1.8 3.33 ± 0.43 9.3 + 1.47 26DVNAS30  35 ± 5.0
Ac-DFNVT-(pNF)-NH 2  34.6 ± 0.5 1.22 ± 0.07 28.4 _ 1.80 26DFNVT30  43 ± 1.6
Ac-DVNAT-(pNF)-NH 2  32.1 ± 1.1 1.06 ± 0.05 30.3 ± 1.96 26DVNAT30 53 ± 3.2
Ac-DQNAT-(pNF)-NH 2 34.8 ± 1.2 0.80 ± 0.11 43.4 ± 6.73 26DQNAT 30 60 ± 4.5
Conclusion
To determine the acceptor specificity of the C. jejuni oligosaccharyltransferase PglB, a library of
peptidyl substrates was synthesized and assayed in vitro. Each peptide differed by a single
amino acid so that the contributions of each residue position could be systematically evaluated.
The minimum glycosylation consensus sequence was determined to be Asp/Glu-XI-Asn-X 2-
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Ser/Thr, where X can be any amino acid except for proline. Interestingly, although our limited
list of known C. jejuni glycoproteins do not display a preference for residues Asp or Glu at
position -2, and residues Ser and Thr at position +2, our sensitive assays revealed a distinct
preference for Asp and Thr at those positions, respectively. Furthermore, trends can be observed
for the two middle positions, where amido and aromatic residues are preferred at Xi, while small
and positively charged residues are preferred at X2.
To determine whether PglB has the ability to glycosylate fully folded proteins independent of the
translocation machinery, the minimum glycosylation consensus sequence was engineered into a
non-C. jejuni protein which is not naturally glycosylated. When PglB was incubated with this
fully folded protein in vitro, glycosylation was confirmed. This ability is unique to PglB, as the
eukaryotic OT can only glycosylate unstructured and flexible acceptors. The efficiency of
glycosylation was improved when the glycosylation site was engineered to contain the optimal
sequence as determined by the peptide study, demonstrating that the trends and preferences
observed in the peptide study of PglB are relevant in the context of a folded protein.
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Experimental
Peptide Synthesis.
All peptides were synthesized by automated peptide synthesis on an ABI 431A peptide
synthesizer (Applied Biosystems) using standard Fmoc-based peptide synthesis conditions on
PAL-PEG-PS resin. Each peptide was acetylated at the N-terminus, and includes a para-
nitrophenylalanine (pNF) at the C-terminus. The peptides were cleaved from the resin using a
trifluoroacetic acid cocktail containing 2.5% water and 2.5% triisopropylsilane, purified to >_95%
purity by preparative reverse-phase HPLC using a standard water:acetonitrile gradient, and
quantified using the UV absorbance of the pNF amino acid at 280 nm (c = 12,500 M-lcm-1).
Cloning and mutagenesis of lm7.
A pTrc (Im7) vector was provided by Professor Sheena Radford from the University of Leeds,
encoding the native Im7 protein with an N-terminal hexa-histidine tag described elsewhere (23-
25). Introduction of point mutations in Im7 was performed using the Quikchange mutagenesis
kit (Stratagene). All mutants were sequenced to ensure that the gene contained the desired
change.
Expression of lm7 Mutants.
Starting from a 5 mL overnight culture, E. coli strains expressing Im7 variants were grown at 37
'C in LB broth to an OD 600 of 0.6-0.8. At that point, the temperature was reduced to 16 oC and
protein production was induced by the addition of isopropyl-f3-D-thiogalactopyranoside (1 mM).
After 24 h, the cells were harvested by centrifugation (7,500 x g) for 30 min, washed once with a
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0.9% NaCI solution, centrifuged again (7,500 x g) for 30 min, and the cell pellet was frozen at -
80'C until needed.
Purification of Im7 Mutants.
All steps were performed at 40 C. Cell pellets of E. coli strains expressing Im7 variants were
thawed and resuspended in 5% of the original culture volume in buffer L [50 mM Tris-acetate, 5
mM imidazole, pH 8]. The cells were lysed by sonication, followed by centrifugation (142,400 x
g) for 1 h to remove cellular debris and membrane proteins. The supernatant was slowly applied
to a column containing Ni-NTA agarose equilibrated with buffer L. After washing with 5
column volumes of buffer L, the purified protein was eluted with buffer E [50 mM Tris-acetate,
250 mM imidazole, pH 8]. Fractions containing a significant amount of desired protein were
combined, and applied to a Superdex75 gel filtration column (Amersham Biosciences) eluting at
1 mL/min with buffer F [50 mM Tris-acetate, pH 8]. Final samples used were confirmed by
ESI-MS to be within 1 Da of expected mass, and >95% pure by Coomassie staining of SDS-
PAGE.
Synthesis of Radioactive Disaccharide Donor.
Radiolabeled [3H]GalNAc-(al,4)-Bac-(cal)-PP-undecaprenyl was synthesized following a
protocol previously described (10). Briefly, chemically synthesized UDP-Bac and undecaprenyl
phosphate and commercially available [ H]UDP-GalNAc were incubated with the C. jejuni
glycosyltransferases PglC and PglA. The radiolabeled disaccharide product was extracted into a
2:1 mixture of chloroform/methanol, aliquoted, and dried into 1.5 mL tubes, each with
120
approximately 0.3 nmol of disaccharide product (specific activity = 356,000 DPM/nmol,
-100,000 DPM/tube).
Glycosylation of Peptide Substrates Using PglIB.
To a tube containing 0.3 nmol of dried radiolabeled [3H]GalNAc-Bac-PP-undecaprenyl was
added 10 gL of DMSO. Following vigorous vortexing and sonication (water bath) to resuspend
the isoprene-based substrate, 100 gL of 2X assay buffer B [280 mM sucrose, 2.4% Triton X-100
(v/v), 280 mM Hepes pH 7.5], 2 gL of 1 M MnC12, and 6 gLL of PglB membrane fraction
containing approximately 50 ng of enzyme were added, and the volume increased to 190 ttL with
water. Reactions were initiated by the addition of 10 gL of peptide substrate dissolved in
DMSO. Aliquots (35 pL) of the reaction mixture were removed at 4 min time intervals up to 20
min and quenched into I mL of 3:2 chloroform:methanol + 200 gL of 4 mM MgC12. The
aqueous layer was extracted and the organic layer was washed twice with 300 xL of pure solvent
upper phase. The aqueous layers were combined, mixed with 5 mL of EcoLite scintillation fluid
(MP Biomedicals), and subjected to scintillation counting. Eight reactions were set up in parallel
in each assay, and all assays were carried out in duplicate or better.
Glycosvlation of Protein Substrates Using PglB.
The reaction protocol is similar to the above procedure for peptide glycosylation, with the
modification that 50 g1 L of PglB membrane fraction was used to glycosylate 13 1iL of a 0.75 mM
stock of Im7 protein acceptor in buffer P. The final concentrations for the protein and the glycan
were 50 gM and 1.5 gM respectively. The reaction was left shaking at room temperature for 3
hours before being spun at high speed to pellet the membrane fraction. The supernatant was
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applied to a Ni-NTA spin cartridge (Qiagen), washed and eluted according to manufacturer
instructions. A 100 pL aliquot of the elution fraction was injected onto an analytical reverse-
phase C18 HPLC column and eluted under a standard water/acetonitrile gradient. Fractions were
collected every minute, mixed with EcoLite scintillation fluid (MP Biomedicals), and subjected
to scintillation counting. Experiments using eukaryotic glycosyl donors were carried out using
the same general procedure. For mass spectral analysis, a 5 nmol aliquot of unradiolabeled sugar
donor was used as the glycosyl donor.
Circular Dichroism Evaluation of Acceptor Proteins.
Far-UV CD spectra were acquired on an Aviv Model 202 spectropolarimeter (Aviv Biomedical)
using a 1 mm path length cell and a protein concentration of 250 tg/mL in buffer C [50 mM
sodium phosphate, 400 mM sodium sulfate] at 25oC.
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CHAPTER 6
POLYISOPRENE SPECIFICITY IN THE PGL PATHWAY
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In N-linked glycosylation, a glycan is assembled on a polyisoprenol-carrier by a series of
glycosyltransferases. The completed glycan is then transferred by an oligosaccharyltransferase
(OT) from the polyisoprenol-carrier to the acceptor protein (1). The substrates for both of the
glycosyltransferases and the oligosaccharyltransferase are amphiphilic, with the polyisoprene
being hydrophobic and embedded within the membrane, while the glycan is hydrophilic and is
present in solution at the membrane interface (Figure 6-1). The recognition of these amphiphilic
substrates by their membrane-associated enzymes is a poorly understood phenomenon due to the
difficulties of studying these enzymes in vitro and of obtaining the appropriate polyisoprenol-
linked substrates. One particular question of interest is whether the polyisoprenol-carrier plays a
simple physical role as a hydrophobic membrane anchor to keep the glycan where the enzymes
are localized, or whether they interact with the enzymes and play a more specific role in
substrate recognition.
hydrophilic glycan I
HHOO OH
undecaprenyl diphosphate-heptasaccharide
hydrophobic polyisoprene
Figure Extended structure of Campylobacterjejuni native glycan donor substrate.
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The recently characterized N-linked protein glycosylation (Pgl) pathway from the gram-negative
bacterium Campylobacter jejuni offers a unique opportunity to study the interaction between
such enzymes and their polyisoprenol-linked substrates (Figure 6-2) (1,2). Firstly, the Pgl
pathway offers a topologically diverse set of enzymes ranging from those that have numerous
predicted transmembrane domains to those with none, and each of these enzymes can be
overexpressed and purified for in vitro analysis. Secondly, as described in Chapter 4, we have
the ability to synthesize highly-pure, specifically radiolabeled substrates and substrate analogs,
which can be used to probe any enzyme within the Pgl pathway (3,4). In this study, we will
carry out the first systematic study to investigate whether the structure of the polyisoprenol-
carriers affects enzyme recognition, and if so, whether these effects are correlated with the
degree of membrane association of the enzyme.
Oligosaccharide
Synthesis
PgI FED PgI K
UDP-u -+ UDP- PglC PgI A PgIJ -PgH Pgll
P PCytosol
PP g Periplasm
Undecaprenyl Phosphate Pg L lycoprotein
* GIcNAc
* GalNAc
A Glucose
0 Bacillosamine
Figure 6-2. C. jejuni N-linked glycosylation pathway.
The three candidate enzymes from the Pgl pathway for this study include PglC, PglJ, and PglB,
which differ significantly in the degree of membrane association and localization within the
pathway (Figure 6-4). The glycosylphosphotransferase PglC transfers 2,4-diacetamido-
bacillosamine phosphate (from here on referred to as simply bacillosamine phosphate) to
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undecaprenyl phosphate to afford the first polyisoprenol-linked intermediate in the pathway
(Figure 6-3) (4). PglC is predicted to contain a single N-terminal transmembrane domain of 22
amino acids (TMHMM, ExPASY) and a large cytoplasmic domain. An intermediate step in the
pathway is catalyzed by PglJ, a glycosyltransferase, which transfers a GalNAc to undecaprenyl
diphosphate-bacillosamine (3). PglJ is not predicted to include any transmembrane domains
(TMHMM, ExPASY), but may contain an N-terminal hydrophobic domain, which is postulated
to interact with the bacterial membrane.
HO OHO
HHO O AcHN
HOoAHN\ undecaprenyl diphosphate-trisaccharide
O-UDP H AcHN 0
UDP-GalNAc PglC & PglA
HO O- O -O OH 3
ud -O -3 0703HO
undecaprenylundecaprenyl diphosphate-hisaccharide AcdN
peptide cHN
undecaprenyl-PP H" N v, . N NH2--H O H OH
N-linked glycosylated peptide product
Figure 6-3. Summary of PglC, PglA, PglJ, and PglB enzyme reactions used in this study.
The final step in the pathway is catalyzed by the OT, PglB, which transfers the completed
heptasaccharide from the undecaprenyl diphosphate-carrier to the protein acceptor (Figure 6-3)
heptasaccharide from the undecaprenyl diphosphate-carrier to the protein acceptor (Figure 6-3)
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(5). PglB comprises 10-12 predicted transmembrane domains from residues 1-425 (TMHMM,
ExPASY) and a C-terminal periplasmic domain from residues 426-703. These three enzymes
conveniently provide a panel of proteins that span the spectrum of membrane association,
ranging from zero to multiple integral membrane regions (Figure 6-4). Since the polyisoprene is
embedded within the membrane, one might hypothesize that the more transmembrane domains
an enzyme contains, the more it might interact with the polyisoprene, and the more
discriminating it will be towards the polyisoprene structure.
PglC TMHMM postenor p owbies for Sequenoe
20 40 80 80 100 120 140 150 180 20
tgJTrts111'sreld -- rtsie - Sq.
PgJ TMHMM posteri probaWe for Sequence
50 100 10 200 250
P lB TMH posterior atis Seqece
PgIB TMHHMA posterior pinobabimesi for Sequermr
300 350
0 !00 200 300 400 500 600 700
tFigure 6-4. TMHMM ExPASY predicted transme domains PgC, PglJ, and PglB.
Figure 6-4. TMHMM, ExPASY predicted transmembrane domains of PglC, PglJ, and PglB.
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6-1. Synthesis of polyisoprenyl-linked substrates
In order to explore the determinants that mediate the enzyme interaction with their amphiphilic
substrate, a set of polyisoprenols of varying length, degrees of saturation, and double-bond
geometry were obtained from our collaborators at the Polish Academy of Science who derived
the pure polyisoprenols from natural plant sources (Figure 6-5) (6,7). The native polyisoprenol
in the C. jejuni N-linked glycosylation pathway is undecaprenol, which contains 11 unsaturated
isoprene units, with cis (Z) double-bond geometry at the a-isoprene unit and an array of trans (E)
and cis isoprene units in the remainder of the structure. Although they share the same name, our
undecaprenol was isolated from the plant Magnolia kobus which contains a 7:3 cistrans ratio,
while the undecaprenol found in bacterial sources is slightly different with an 8:2 ratio. To
determine the effect of polyisoprenol length on enzyme activity, we obtained prenol-9 and
prenol-8, which are very similar to undecaprenol in saturation and double bond geometry, but
contain two and three fewer isoprene units respectively. To determine the effect of double-bond
geometry, we obtained solanesol and geranylgeraniol, which consist exclusively of trans double-
bonds, rather than a mixture of cis and trans isomers. Prenol-9 provides a convenient length
control for solanesol because these two polyisoprenols contain the same total number of isoprene
units. Finally, to determine the effect of the a-isoprene saturation, we obtained dihydroprenol- 11
and the dolichols, which are respectively either the same length as undecaprenol or longer, and
are both saturated at the a-isoprene unit. This results in a sp3-hybridized tetrahedral carbon
adjacent to the alcohol rather than a planar sp2-hybridized carbon center of the native
undecaprenol. The dolichols are particularly interesting because they constitute part of the native
substrates in the eukaryotic N-linked glycosylation pathways (8).
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Prenol-9
Dihydroprenol-11
Dolichol
Prenol-8
Undecaprenol OH
(native)
0 H H 1-3
Geranylgeraniol
K K K K . K K K OH Solanesol
Figure 6-5. Polyisoprenols used in this study.
The polyisoprenols were incorporated into substrates for the enzymes PglC, PglJ and PglB using
a chemoenzymatic approach (Figure 6-6). To make the appropriate substrates for PglC, each
polyisoprenol was chemically phosphorylated (9,10) to afford the polyisoprenyl phosphate. To
makes the appropriate substrates for PglB and PglJ, these polyisoprenyl-phosphates were
converted to the respective polyisoprenyl diphosphate-bacillosamine-[3H]GalNAc using PglC
and the glycosyltransferase PglA as described in Chapters 4 and 5. Although the native substrate
for PglB is an undecaprenyl diphosphate-linked heptasaccharide donor, the bacillosamine-
[3H]GalNAc disaccharide was used in our in vitro assays of PglB because of its easier synthesis
and better solubility properties as described in Chapter 5 (5). The overall yield of the
disaccharide synthesis using PglC and PglA depended on the identity of the polyisoprenyl
phosphates. By using an excess UDP-bacillosamine and UDP-GalNAc to drive the reaction,
typical yields ranged between 20-70% for a 50 nmol scale preparation. The disaccharide
products were separated from the unreacted polyisoprenyl phosphates using normal phase HPLC
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and characterized by ESI-MS. The [3H] radiolabel offers a convenient means to accurately
quantify both substrates and products in the low micromolar concentration range. This
chemoenzymatic synthesis once again demonstrates the versatility of our approach for accessing
polyisoprenol-linked glycan substrates for biochemical studies.
UDP-bacillosamine HO3H 3H UDP-[ 3 H]GalINAc
AcHN O 
OH
AcHN AcHNO-UDP O-UDP PgIC & PgIA
- UMP, UDP/ A-o-P-OH UMP, UDP
--- /I \1 / n
polyisoprenyl-phosphate
(substrate for PglC)
chemical
phosphorylation
(9,10)
\m
polyisoprenyl-diphosphate disaccharide
(substrate for PglB and PglJ)
Undecaprenol
Prenol-9
Prenol-8
Dihydroprenol-1 1
Dolichol 17-19
Solanesol
Geranylgeraniol
= 3, m =7, n = 0
= 3, m =5, n = 0
= 2, m = 5, n= 0
I = 3, m = 6, n= 1
I = 2, m = 13-15, n = 1
I = 8, m = 0, n = 0
I = 3, m = 0, n = 0
/ polyisoprenol
Figure 6-6. Synthesis of polyisoprenyl phosphate and polyisoprenyl diphosphate-disaccharide
as substrates for PglC, PglB, and PglJ.
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6-2. Comparison of polyisoprenyl-substrate analogues with PglB
m AcHN peptide O0P 0 'kL
I IAcHNO-j~--OH polyisoprenyl-PP OH AcHN NH
O O HO H H
AnN N N N NNtHN
polyisoprenyl-diphosphate disaccharide H H 0 H O
N-linked glycosylated peptide product
Figure 6-7. PglB in vitro assay reaction.
With purified substrates and detergent solubilized enzymes, steady-state kinetic assays were
performed to determine the specificity of PglC, PglJ and PglB for each of the different
polyisoprenol-containing substrate analogs. To assay for PglB activity, the transfer of
radiolabeled glycan from the organic soluble polyisoprenyl diphosphate donor to the aqueous
soluble peptide acceptor was monitored (Figure 6-7). The peptide acceptor used in this study
was the hexapeptide Ac-DFNVT-(pNF)-NH2 where pNF is para-nitrophenylalanine described in
Chapter 5 as providing a convenient chromophore for peptide concentration quantification (11).
The peptide was used at saturating concentrations and the amount of the polyisoprenyl
diphosphate-linked disaccharide substrates was varied to afford the results shown. The reaction
rates with the prenol-9 and prenol-8 analogs are very similar to that of the native undecaprenol
(Figure 6-8B). This suggests that PglB is not affected by the presence of a slightly truncated
form of undecaprenol. The use of dihydroprenol-11 and dolichols, both of which include a
saturated terminal a-isoprene unit, resulted in a significant decrease in PglB activity suggesting
that PglB is sensitive to the degree of saturation proximal to the site of enzymatic action.
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Finally, the solanesol-linked substrate demonstrated the lowest activity with PglB, suggesting
that the all-trans geometry also disrupts interactions between PglB and the polyisoprenol moiety.
Both the KM and Vmn are affected in the case of these non-natural substrates (Table 6-1).
Table 6-1. Kinetic parameters of polyisoprenyl-substrate with Pgl enzymes. PglC and PglJ
initial rates refer to initial reaction rates at 60 CgM polyisoprenyl phosphate and 0.5 ptM
polyisoprenyl diphosphate-disaccharide concentrations respectively. PglB Km values refer to that
of the polyisoprenyl-substrate at saturating peptide acceptor concentration. n.d. = not determined.
PgIC PglJ PglB
Polyisoprenol Initial Rate Initial Rate Vmax Km VmdaxKm
nM/min nM/min nM/min PM min -1 x 103
Prenol-11 (undecaprenol) 210.6 ± 18.1 1.83 ± 0.20 63.2 ± 4.6 2.63 ± 0.36 24.0 ± 5.0
Prenol-9 214.4 + 24.4 1.66 ± 0.11 56.0 ± 5.0 2.97 + 0.50 18.9 ± 4.8
Prenol-8 183.8 + 6.2 n.d 64.4 ± 6.9 2.77 ± 0.56 23.2 ± 7.2
Dihydroprenol-11 57.5 + 5.6 0.67 ± 0.05 24.4 ± 2.0 5.87 ± 0.82 4.2 ± 0.9
Dihydroprenol-17-19 (dolichols) 50.6 + 5.1 0.54 ± 0.03 16.6 ± 1.3 4.23 ± 0.53 3.9 ± 0.8
all-trans Prenol-9 (solanesol) 3.8 ± 2.0 0.54 ± 0.07 8.5 ± 0.8 4.06 ± 0.68 2.1 ± 0.6
all-trans Prenol-4 (geranylgeraniol) 0.6 ± 1.0 n.d n.d. n.d. n.d.
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Figure 6-8. Comparison of enzyme reaction rates at varying concentrations of polyisoprenyl-
linked substrates: J) glycosyltransferase PglJ, B) oligosaccharyltransferase PglB, and C)
glycosylphosphotransferases PglC. Adjacent bar graph results are described in Table 6-1. All
assays were carried out in duplicate or better with representative data set shown.
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6-3. Comparison of polyisoprenyl-substrate analogues with PglC
UDP-bacillosamine(60H) UDP-GalNAc
OH HOHH 3
AcHN AAHN AcHNO-UDP O-UDP HO AcHN i
O- -OH UMP,UDP 
-
I nn
polyisoprenyl-phosphate polyisoprenyl-diphosphate disaccharide
Figure 6-9. PglC in vitro assay reaction.
In the same manner, PglC was assayed against each of the polyisoprenyl phosphates by Dr.
Eranthie Weerapana from our laboratory (4). The UDP-bacillosamine(60H) analog was used as
the glycosyl-phosphate donor since it is known to be accepted by PglC with comparable
efficiency as the native UDP-bacillosamine (4) and was more readily available at that time
because of its shorter chemical synthesis. To assay for PglC activity, a coupled assay involving
PglA (Figure 6-9) (4) was used because of the lack of a radiolabeled UDP-bacillosamine to
directly assay PglC at the time the assays were carried out. A large excess of PglA was used to
ensure that reaction rates reflected the rate limiting PglC step, and that the rates measured did not
change when additional PglA was added. The assay for PglC activity monitored the transfer of
radioactivity from the aqueous soluble UDP-[3H]GalNAc to the organic soluble polyisoprenyl
diphosphate-substrate. Figure 6-8C illustrates the reaction rates using each of the different
polyisoprenyl phosphates as substrates for PglC. Similar to the substrate selectivity
demonstrated by PglB, PglC accepts prenol-8 and prenol-9 with equal efficiencies to the native
undecaprenol-based substrate. Dolichols-, and dihydroprenol-11, substrates were accepted with
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approximately four-fold decrease in activity, suggesting that PglC is sensitive to the saturation of
the a-isoprene unit. Finally, the all-trans solanesyl and geranylgeranyl phosphates were
extremely poor substrates for PglC suggesting that the isoprene-geometry plays a critical role in
substrate recognition.
6-4. Comparison of polyisoprenyl-substrate analogues with PglJ
H3H H
HO3HOH
AcHPgJ AcH
HO AcHN 0 HO AcHN O
mAMINo UMP m
Of-O-l--OH UDP-GalNAc O---OH
polyisoprenyl-diphosphate disaccharide polyisoprenyl-diphosphate trisaccharide
Figure 6-10. PglJ in vitro assay reaction.
PglJ is the peripheral membrane protein that transfers the third sugar in the heptasaccharide
biosynthesis. The PglJ enzyme samples used in this study were purified to homogeneity using
Ni-NTA affinity chromatography as previously described (3). The same purified radiolabeled
disaccharide substrates used in the PglB assay above, were also used to assay PglJ activity. In
this case, since the disaccharide acceptor is already radiolabeled, we simply measured the
increase in radioactivity resulting from the transfer of an additional GalNAc residue from UDP-
[3H]GalNAc (Figure 6-10). Similar to PglB and PglC, PglJ accepts the prenol-9 substrate with
equal efficiencies to the native undecaprenol-linked substrate (Figure 6-8J). The non-natural
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dihydroprenol-11, dolichols and solanesol-linked substrates are also accepted by PglJ but with
lower reaction rates compared to the corresponding undecaprenol and prenol-9 substrates.
Our studies reveal that each of the three enzymes from the Pgl pathway exhibit distinct
preferences for the structural features of the polyisoprenols within their target substrates. In
comparison to the native undecaprenol-based substrates, polyisoprenol-substrates of shorter
length, such as prenol-9 and prenol-8, displayed similar turnover, indicating that all three
enzymes do not have stringent specificity for the number of isoprene units; the C40 prenol-8 is
virtually identical in activity to the C55 native undecaprenol. Although solanesol is of the same
length as prenol-9, its incorporation into substrates for each of the enzymes proved highly
deleterious, most likely due to the unfavorable all-trans double bond geometry. Furthermore,
dihydroprenols such as dolichols, being saturated at the a-isoprene position, were also poorly
accepted in comparison to the unsaturated counterparts. This clear specificity with respect to the
polyisoprenol-carrier, especially towards the features at a-isoprene units, is consistent with the
hypothesis that membrane-associated hydrophobic proteins interact extensively with their
lipophilic substrates. Intriguingly, there was no clear correlation between the stringency of the
substrate specificity and the number of predicted transmembrane domains possessed by each
enzyme.
We considered the possibility that the differences observed in Vmax and KM do not actually reflect
differences in catalytic efficiencies or their binding affinities to the enzymes, but rather a
function of substrate solubility as well as, in the case of PglB and PglC, enzyme accessibility
which is limited by the permeability of the cell membrane. However, the concentration of
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detergent used in the assay conditions was sufficient for fully dissolving the cell membrane, and
therefore the interaction of the polyisoprenyl-linked substrates should not be influenced or
limited by the membrane structure (12). Furthermore, the detergent is known to form mixed
micelles with the substrate, such that each polyisoprenyl-linked substrate should be effectively
solubilized (13).
These studies concur with a previous report on the N-linked glycosylation pathway of
Saccharomyces cerevisiae, whereby polyisoprenyl-specificity was found to be maintained by
both Alg7 and the OT, the two eukaryotic enzymes that catalyze the analogous reactions to PglC
and PglB (14). However, since Alg7 did not accept any a-unsaturated polyisoprenyl phosphates
or the all-trans solanesyl phosphate, the corresponding OT substrates could not be accessed and
therefore the study could not be pursued to the level of detail presented herein for the C. jejuni
enzymes. To our knowledge, the specificity of OT towards a-unsaturated and all-trans
polyisoprenols has not been previously tested in any other systems. A simplified generalization
has been that a-unsaturated polyisoprenols are primarily found in bacteria and plants, while
dihydropolyisoprenols are present in mammalian and yeast cells (6). Therefore, many examples
of glycosyltransferases from eukaryotic and prokaryotic sources have been found to reflect this
specificity towards their native type of polyisoprenol-carrier (15-17). In this case, the in vitro
radioactivity-based assay allowed us to takes advantage of the versatility of a chemoenzymatic
synthesis to evaluate unnatural substrates for the bacterial OT. Interestingly, all three enzymes
appear capable of accepting the eukaryotic dolichol-based carrier in vitro albeit with lower
reaction rate.
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Conclusion
Using the N-linked glycosylation pathway of C. jejuni as a model system for the study of how
membrane-associated enzymes interact with their lipophilic substrates, we selected three
enzymes from this pathway, PglC, PglJ, and PglB, which have varying degrees of membrane-
association. A set of polyisoprenols varying in length, degrees of saturation, and double-bond
geometry were obtained from natural sources and converted into the respective substrates for
these three enzymes using a chemo-enzymatic synthesis. We found that each enzyme displayed
the same specificity and preferences towards the set of polyisoprenyl-linked substrates, whereby
the overall length of the polyisoprene did not affect enzyme activity, but changes to the structure
of the a-isoprene led it being a poorer substrate for the enzyme. This specificity towards the
polyisoprenol portion of the substrate by all three enzymes suggests that the polyisoprenol does
not play merely a physical role as a hydrophobic membrane anchor, but interacts with the
enzymes from the pathway and is involved in substrate recognition.
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Experimental
UDP-sugar Donors.
UDP-bacillosamine was synthesized enzymatically from UDP-GlcNAc using the PglF, PglE, and
PglD enzymes from the C. jejuni pathway as described previously in Chapter 4 (18). The
preparation of UDP-bacillosamine(60H), which is a synthetic intermediate in the chemical
synthesis of UDP-bacillosamine was carried out as reported previously (4,19). Radiolabeled
UDP-[3H]GalNAc was purchased from American Radiolabeled Chemicals Inc.
Polyisoprenol Isolation & Phosphorylation.
Solanesol and geranylgeraniol were purchased from Sigma-Aldrich. All remaining
polyisoprenols were isolated from diverse plant sources (7) and purified from the natural extracts
by chromatographic methods (20). Undecaprenol was from Magnolia kobus leaves, prenol-9 was
from the Tilia cordata leaves, prenol-8 was from the wood of Betula veruccosa, and prenols-17-
19 were from Ginkgo biloba leaves. Hydrogenation of undecaprenol resulted in a racemic
mixture of dihydroprenol-11 (21). Dolichols-17-19 were synthesized via asymmetric
hydrogenation of prenols-17-19 (22). Undecaprenol, dolichols, solanesol, and geranylgeraniol
were chemically phosphorylated using phosphoramidite chemistry (9,10). Prenol-9, prenol-8,
were phosphorylated with phosphoric acid and trichloroacetonitrile (23). Dihydroprenol-11 was
phosphorylated with phosphorus oxychloride (24). The purity of the polyisoprenyl-phosphates
was evaluated by thin layer chromatography and determined to be >95% in all cases.
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Enzyme Purification.
The expression and purification of PglA (3), PglJ (3), PglC (4), and PglB (5) enzymes have been
previously described in detail. For this study, both PglA and PglJ were further subjected to an
additional chromatographic purification on a Sephacryl 300 gel filtration column (GE
Healthcare). PglA and PglJ were evaluated to be 95% pure by SDS PAGE, while PglC and PglB
were used as a semi-pure membrane fraction necessary for preserving enzyme stability.
Enzymatic synthesis of Radiolabeled Polyisoprenyl Diphosphate Disaccharide Donors.
3 H
OH
ACHN
HO AcHN0 0
0- 01 O 1
n
To an eppendorf tube containing 50 nmol of the polyisoprenyl-phosphate was added 6 tL
DMSO and 14 jiL of 14.3% (v/v) Triton X-100. After vortexing and sonication (water bath), 42.5
pL of H20, 5.5 ptL of I M Tris-acetate (pH 8.0), 2 gL of 1 M MgC12, 20 pL of 5 mM UDP-
Bac2,4diNAc, 20 gL of 2.5 ItM UDP-GalNAc (specific activity = 152 nCi nmol-1), 70 tL of
PglA, and 40 ptL of PglC were added. The concentrations of enzyme stock solutions used were
approximately 500 mg mL' and 250 mg mL 1 for PglA (3) and PglC (4) respectively. Reactions
were left shaking at room temperature for 3 hours then quenched by the addition of 800 pL 2:1
chloroform:methanol and 100 pL of pure solvent upper phase (PSUP; 3% chloroform, 49%
methanol, and 48% water with 100 mM KC1). After brief vortexing, the layers were allowed to
separate and the aqueous layer was removed. The organic layer was washed three times with 200
pL of PSUP, dried under a stream of nitrogen, and then redissolved in 100 pL of 4:1
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chloroform:methanol. The crude product was then purified by HPLC on a Microsorb 60 Si
normal phase column (Varian), eluting with a linear gradient of 100% solvent C (4:1
chloroform/methanol) to 100% solvent D (10:10:3 chloform/methanol/2 M ammonium acetate
pH 7.2) over 50 min at a flow rate of 1 mL/min. Fractions containing significant amount of
radiolabeled product were combined and immediately aliquoted, dried, and stored at -80 oC until
needed.
PglJ Radioactivity Assay.
To a tube containing a specified amount of dried radiolabeled polyisoprenyl diphosphate
Bac2,4diNAc-[ 31H]GalNAc were added 10 gL DMSO and 7 gL of 1.43% (v/v) Triton X-100.
After vortexing and sonication (water bath), 5 p.L of 1 M Tris-acetate (pH 8.0), 1 gL of 1 M
MgCl 2, 5gL of 50 mM DTT, 62 gL of H20, and 5 pL of 500 mg mL- PglJ were added. For
negative control reactions (not shown), the PglJ samples were replaced by 50 mM Tris-acetate
buffer (pH 8.0). Four reactions containing different amounts of polyisoprenyl diphosphate
disaccharides were carried out in parallel. The reactions were initiated by the addition of 5 gL of
1 gM radiolabeled UDP-GalNAc (specific activity = 19.8 gCi nmol'-, KM(UDP-GalNAc) -1
1 M). All assays were carried out at 22 ±+ 1 C, and 17 gL aliquots were taken at 2, 4, 6, and 8
min. Reactions were quenched by addition to an eppendorf tube containing 800 gL 2:1
chloroform/methanol and 200 gL of PSUP (25). After brief vortexing, the layers were allowed to
separate and the aqueous layer was removed. The organic layer was washed two times with 100
pL of PSUP and dried under a stream of nitrogen. The residue was then redissolved in 200 gL of
DMSO by vigorous vortexing followed by the addition of 5 mL of EcoLite scintillation fluid
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(MP Biomedicals) and subjected to scintillation counting (5 min per sample). All assays were
carried out in duplicate or better.
Peptide Synthesis.
OH NH2
o o OH
H H HN 0 N
N N N N NH2H H H
O O 
NO2
The Ac-DFNVT-(pNF)-NH 2 acceptor peptides was synthesized by automated peptide synthesis on
an ABI 431 A peptide synthesizer (Applied Biosystems) using standard Fmoc-based peptide
synthesis conditions on PAL-PEG-PS resin. This peptide was acetylated at the N-terminus, and
included a para-nitrophenylalanine (pNF) at the C-terminus. The peptides were cleaved from the
resin using a trifluoroacetic acid cocktail containing 2.5% water and 2.5% triisopropylsilane,
purified to >95% purity by preparative Cls reverse-phase HPLC eluting with a linear gradient of
100% solvent A (water with 0.1% TFA) to 100% solvent B (acetonitrile with 0.1% TFA) over 30
min at a flow rate of 15 mL/min, and quantified using the UV absorbance of the pNF amino acid at
280 nm (z = 12,500 M-ccm-i). The KM of this peptide with PglB is 1.21 gM (11).
PglC and PglA Coupled Radioactivity Assay.
PglC was assayed based on procedures described elsewhere (4). To a tube containing a specified
amount of dried polyisoprenyl-phosphate were added 3 gL DMSO and 7 gLL of 14.3% (v/v)
Triton X-100. After vortexing and sonication (water bath), 73 ftL of H20, 4 pL of 1 M Tris-
acetate pH 8.0, 1 [tL of 1 M MgC12, 5 pL of PglA, and 2 tL of PglC. For negative control
reactions (not shown), the PglA and PglC samples were replaced by 50 mM Tris-acetate buffer
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pH 8.0. The concentrations of enzyme stocks used were 500 mg mL-1 and 250 mg mL-' for PglA
(3) and PglC (4) respectively. Four reactions containing different amounts of polyisoprenyl
phosphate were carried out in parallel. The reactions were initiated by the addition of 5 gpL of
sugar mix consisting of 100 jgM UDP-6-hydroxylBac2,4diNAc and 100 gM UDP-GalNAc
(specific activity = 36.1 nCi nmo!', KM(UDP-GalNAc) -2 [M, KM(UDP-60HBac) -4 jgM) Reactions
were carried out at 22 ± I C, and 20 jiL aliquots were taken at 2, 4, 6, and 8 min. Reactions were
quenched by addition to a tube containing 400 jgL 2:1 chloroform:methanol and 200 gL of pure
solvent upper phase (PSUP; 3% chloroform, 49% methanol, and 48% water with 100 mM KC1).
After being vortexed briefly the layers were allowed to separate and the aqueous layer was
removed. The organic layer was washed two times with 400 jPL of PSUP and dried under a
stream of nitrogen. The residue was redissolved in 200 gL of Solvable (Perkin-Elmer) by
vigorous vortexing followed by the addition of 5 mL of Formula 989 scitillation fluid (Perkin-
Elmer). The tubes were allowed to rest for 1 hour and counted in a scintillation counter (5 min
per sample). Eight reactions were set up in parallel in each assay, and all assays were carried out
in duplicate.
PglB Radioactivity Assay.
PglB was assayed based on procedures described elsewhere (11). Briefly, to a tube containing a
specified amount of dried radiolabeled [3H]GalNAc-Bac2,4diNAc-PP-polyisoprenol (specific
activity = 160 nCi nmol') was added 10 jiL of DMSO. Following vigorous vortexing and
sonication (water bath) to resuspend the isoprene-based substrate, 100 pL of 2X assay buffer
[280 mM sucrose, 2.4% Triton X-100 (v/v), 280 mM Hepes pH 7.5], 2 jiL of 1 M MnC12, and 6
jIL of PglB (5) membrane fraction containing approximately 50 ng of enzyme were added, and
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the volume increased to 190 pL with water. Reactions were initiated by the addition of 10 pgL of
2.0 mM peptide acceptor (KM(peptide) = 1.21 p~M) dissolved in DMSO. The reactions were carried
out at 22 + 1 oC, and 35 jtL aliquots of the reaction mixture were removed at 4 min time intervals
up to 20 min and quenched into 1 mL of 3:2 chloroform/methanol and 200 glL of 4 mM MgCl2.
The aqueous layer was extracted and the organic layer was washed twice with 300 itL of PSUP.
The aqueous layers were combined, mixed with 5 mL of EcoLite scintillation fluid (MP
Biomedicals), and subjected to scintillation counting. Eight reactions were set up in parallel in
each assay, and all assays were carried out in duplicate or better. Glycopeptide products have
been previously confirmed for this assay (5).
Mass Spectral Characterization of Unnatural Polyisoprenyl Diphosphate Disaccharide
Substrates.
Mass spectra were acquired using a 4000 QTrap mass spectrometer (Applied Biosystems / Sciex,
Concord, ON, Canada). Capillary electrophoresis was performed using a Prince CE system
(Prince Technologies, The Netherlands). The separation was obtained on a 90 cm length bare
fused-silica capillary (365 itm OD x 50 jLm ID) with CE-MS coupling using a liquid sheath-flow
interface and isopropanol:methanol (2:1) as the sheath liquid. Precursor-ion scanning (m/z 79,
P0 4) for the dolichol sample was done in the negative-ion mode, with a collision energy of 70 V.
Samples were dissolved in 3:1 chloroform/methanol and an aqueous CE buffer consisting of 10
mM ammonium acetate was used for all experiments.
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-English as first language
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